GB2131432A - Preparation of (5R)-penem derivatives - Google Patents

Preparation of (5R)-penem derivatives Download PDF

Info

Publication number
GB2131432A
GB2131432A GB08332756A GB8332756A GB2131432A GB 2131432 A GB2131432 A GB 2131432A GB 08332756 A GB08332756 A GB 08332756A GB 8332756 A GB8332756 A GB 8332756A GB 2131432 A GB2131432 A GB 2131432A
Authority
GB
United Kingdom
Prior art keywords
group
methyl
thiacephem
general formula
prepared according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB08332756A
Other versions
GB2131432B (en
GB8332756D0 (en
Inventor
Marco Alpegiani
Angelo Bedeschi
Maurizio Foglio
Giovanni Franceschi
Ettore Perrone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Farmitalia Carlo Erba SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB838323129A external-priority patent/GB8323129D0/en
Application filed by Farmitalia Carlo Erba SRL filed Critical Farmitalia Carlo Erba SRL
Priority to GB08332756A priority Critical patent/GB2131432B/en
Publication of GB8332756D0 publication Critical patent/GB8332756D0/en
Publication of GB2131432A publication Critical patent/GB2131432A/en
Application granted granted Critical
Publication of GB2131432B publication Critical patent/GB2131432B/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/88—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

(5R)-penem derivatives of the general formula I <IMAGE> (R1=H or an organic group, R2=H or a carboxy protecting group and Y=H, halogen or an organic group) are prepared by oxidising 2-thiacephem derivatives of the general formula II <IMAGE> (R1, R2 and Y as above defined) by means of organic peracids, and submitting the resultant corresponding 1,1-dioxide of formula III to a desulphurative ring contraction with expulsion of SO2. <IMAGE>

Description

SPECIFICATION 2-Thiacephems and (5R) penem derivatives The invention relates to a new process for the preparation of (5R) pen em compounds of the general formula I and their pharmaceutically and/or veterinarily acceptable salts.
In the general formula I, R1 represents a hydrogen atom or an organic group; R2 represents a hydrogen atom or a carboxy protecting group; and Y represents a hydrogen or halogen atom or an organic group.
Organic groups which R1 may represent include optionally substituted aliphatic or cycloaliphatic groups, The aliphatic groups are preferably alkyl groups having from 1 to 1 2 carbon atoms and the optional substituents may be one or more hydroxy, amino, cyano and/or mercapto groups. The hydroxy, amino and mercapto groups may be free or protected. Particularly preferred alkyl groups are methyl and ethyl, especially the latter, and a preferred substituent for such a group is a hydroxy group, which may be free or protected. The 1-hydroxyethyl group in 6S, 8R or 6R, 8S configuration is most preferred.
The cycloaliphatic groups are preferably monocycloalkyl groups having from 4 to 7 carbon atoms.
Cyclopentyl and cyclohexyl groups are especially preferred. Optional substituents are preferably chosen from alkyl groups having from 1 to 6 carbon atoms, for example methyl or ethyl groups, hydroxy, amino and mercapto groups, the hydroxy, amino and mercapto groups being free or protected.
The carboxy protecting group R2 may be any group which, together with the -COO moeity, forms an esterified carboxy group. Examples of carboxy protecting groups R2 are alkyl groups having from 1 to 6 carbon atoms, for instance methyl, ethyl or t-butyl; halo substituted alkyl groups having from 1 to 6 carbon atoms, for example 2,2,2-trichloroethyl; alkenyl groups having from 2 to 4 carbon atoms, for example allyl; optionally substituted aryl groups, for example phenyl and p-nitro-phenyl; aryl substituted alkyl groups, the alkyl part whereof has from 1 to 6 carbon atoms and the aryl part whereof is optionally substituted, for example benzyl, p-nitro-benzyl and p-methoxy-benzyl; aryloxy substituted alkyl groups, the alkyl part whereof has from 1 to 6 carbon atoms, for example phenoxy-methyl; or groups such as benzhydryl, o-nitro-benzhydryl, acetonyl, trimethylsilyl, diphenyl-t-butyl-silyl, and dimethyl-t-butyl-silyl. The definition of R2 as a carboxy protecting group also includes any residue, such as acetoxymethyl, pivaloyloxymethyl or phthalidyl, leading to an ester group which is known to be hydrolyzed "in vivo" and to have favourably pharmacokinetic properties.
When Y represents a halogen atom, it is preferably a fluorine, chlorine or bromine atom.
When Y represents an organic group, it is preferably a) a free or protected hydroxy group; b) a formyloxy group or an acyloxy group having from 2 to 6 carbon atoms, optionally substituted by a halogen atom, by an acyl group having from 2 to 6 carbon atoms, or by an amino, hydroxy or mercapto group, the amino, hydroxy or mercapto group optionally being in a protected form; c) an unsubstituted or N-alkyl or N-acyl substituted carbamoyloxy group; d) an alkoxy group having from 1 to 12 carbon atoms or an alkylthio group having from 1 to 12 carbon atoms, either of which is optionally substituted by one or more halogen atoms, formyl groups, acyl groups having from 2 to 6 carbon atoms, and/or amino, hydroxy or mercapto groups, the amino, hydroxy or mercapto group optionally being in a protected form;; e) a 1-pyridinium group, unsubstituted or substituted in the meta or para position with the group --CONH,; f) a heterocyclylthio group -5-Het wherein Het, denoting a saturated or unsaturated heterocyclic ring containing at least one oxygen, sulphur and/or nitrogen heteroatom, is preferably:: A) a pentatomic or hexatomic heteromonocyclic ring, containing at least one double bond and at least one oxygen, sulphur and/or nitrogen heteroatom, unsubstituted or substituted by one or more a') alkoxy groups having from 1 to 6 carbon atoms, aliphatic acyl groups having from 2 to 6 carbon atoms, hydroxy groups and/or halogen atoms; b') alkyl groups having from 1 to 6 carbon atoms, unsubstituted or substituted by one or more hydroxy groups and/or halogen atoms; c') alkenyl groups having from 2 to 6 carbon atoms, unsubstituted or substituted by one or more hydroxy groups and/or halogen atoms;; d') groups of the general formula -S-R3 wherein R3 represents a hydrogen atom or an alkyl group having from 1 to 6 carbon atoms, or groups of the general formula -S-CH2-COOR4 wherein R4 represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms or a carboxy-protecting group; e') groups of the general formulae (CH2)rnC0OR4 or -CHCH-COOR4 or (CH2)rnCN or (CH2)rnCONH2 or -(CH2)-SO3H wherein m is zero, 1, 2 or 3 and R4 is as defined above; f') groups of the general formula
wherein m is as defined above, and each of R5 and R6, which may be the same or different, represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms or an aliphatic acyl group or when one of R5 and R6 is hydrogen, the other may be also an amino protecting group; or B) a heterobicyclic ring, containing at least two double bonds wherein each of the condensed heteromonocyclic rings, being the same or different, is a pentatomic or hexatomic heteromonocyclic ring containing at least one oxygen, sulphur or nitrogen heteroatom, said heterobicyclic ring being unsubstituted or substituted by one or more substituents selected from a'), b'), c'), e') and f') as defined above.
In the above definitions A) and B) preferred halogen atoms are chlorine, bromine and iodine; preferred alkyl groups are methyl and ethyl; a preferred alkenyl group is allyl; a preferred aliphatic acyl group is acetyl; a carboxy protecting group may be any of the groups previously indicated for the R2 substituent; and the free sulpho and carboxy groups possibly present may be salified, e.g. as sodium or potassium salts. A heteromonocyclic ring of the above class A) may be, for example, an optionally substituted thiazolyl, triazolyl, thiadiazolyl, tetrazolyl or triazinyl ring.Preferred substituents on such rings are, for example, one or more substituents chosen from amino, hydroxy, oxo and a C1-C6-alkyl group, preferably methyl or ethyl, wherein the C1-C6-alkyl group may be optionally substituted by a substituent chosen from carboxy, sulpha, cyano, carbamoyl, amino, methylamino or dimethylamino. A heterobicyclic ring of the above class B) may be for example, a tetrazolopyridazinyl radical optionally substituted by amino or carboxy.
In the above formula I the amino, hydroxy or mercapto protecting groups possibly present may be those usually employed in the chemistry of penicillins and cephalosporins for these functions. They may be, for instance optionally substituted, especially halo-substituted, acyl groups, e.g. acetyl, monochloroacetyl, dichloroacetyl, trifluoroacetyl, benzoyl orp-bromophenacyl; triarylmethyl groups, in particular triphenylmethyl; siiyl. groups, in particular trimethylsilyl, dimethyl-t-butyl-silyl, diphenyl-tbutyl silyl; or also groups such as t-butoxycarbonyl,p-nitrobenzyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, benzyl, pyranyl and nitro.When, in particular, the R1 substituent in formula (I) is a hydroxyalkyl group, preferred protecting groups for the hydroxy function are p-nitro-benzyloxycarbonyl; dimethyl-t-butyl-silyl; diphenyl-t-butylsilyl; trimethylsilyl; 2,2,2-trichloroethoxycarbonyl; benzyl; p-bromo-phenacyl; triphenylmethyl and pyranyl. All the alkyl and alkenyl groups, including the aliphatic hydrocarbon moiety of the alkoxy, alkylthio and acyloxy groups, may be branched or straight.
The pharmaceutically and/or veterinarily acceptable salts may be both salts with acids, either inorganic acids such as hydrochloric or sulphuric acid, or organic acids such as citric, tartaric, fumaric or methanesulphonic acid, and salts with bases, either inorganic bases such as alkali metal or alkalineearth metal hydroxides, in particular sodium and potassium hydroxides, or organic bases such as triethylamine, pyridine, benzylamine or collidine. Preferred salts are the salts of the compounds of formula I wherein R2 represents a hydrogen atom with one of the bases hereabove specified in particular with sodium hydroxide or potassium hydroxide.
The compounds of the general formula I obtainable by the process of the invention are known compounds, described in our British Patent Specifications Nos. 2043639A and 8210410. They are potent, broad-spectrum antimicrobial agents, and are therefore useful in the treatment of bacterial infections in warm-blooded animals, especially in humans, by enteral or parenteral administration.
Desulphurative ring contraction of 2-thiacephem of the general formula II
wherein R1, R2 and Y are as above defined is a known process for the preparation of penems, but it suffers from poor or adverse stereoselectivity. Although the carbon atom in position 6 has the R configuration, the desulphurization usually gives (5S)-penems which are biologically inactive (H. R.
Pfaendler et al., J. Am. Chem. Soc., 101, 1979, 6306) or a mixture of (5S)-and (5R)-penems (A.
Henderson et al., J. Chem. Soc. Commun., 1982, 809). We have found and described in Tetrahedron Letters, 24, pag. 3283 (1 983) that (5R)-penems can be obtained from such desulphurative ring contractions if the substituents R1, R2 and Y and the solvent for the process are suitably selected. A more general stereoselective process, operable over the full range of values of the substituents R1, R2 and Y is, however, clearly desirable, as it would obviate the losses involved in the formation of the undesired (5S)-isomers and their separation from the desired (5R)-isomers.
The invention provides a process for the preparation of a (5R)-penem having the general formula I as above defined the process comprising oxidising a 2-thiacephem having the general formula Il as above defined and wherein the carbon at position 6 has the R configuration to give a sulphone having the qeneral formula Ill
wherein R1, R2 and Y are as above defined, and ring contracting the sulphone by extrusion of sulphur dioxide; and, if desired, converting the resultant (5R) penem of the general formula I into another compound of the general formula I; and/or, if desired, converting the resultant compound of the general formula I into a salt thereof; and/or, if desired, obtaining a free compound of the general formula I from a salt thereof.
The oxidation may be carried out using oxidizing agents usually used to convert an organic sulphide into the corresponding sulphate. Preferred oxidizing agents are peracids such as mchloroperbenzoic acid or peracetic acid. The reaction is generally performed in an organic solvent, such as chloroform or benzene, at a temperature of from 0 to 600C, preferably from 4 to 300C.
The ring contraction of the sulphate, with loss of sulphur dioxide, may be effected simply by heating it in an inert organic solvent such as chloroform or benzene. The ring contraction may, in some cases, even occur spontaneously at room temperature. The R configuration of the carbon atom in position 6 in the 2-thiacephem II is retained throughout the process, so that (5R)-penems are obtained exclusively. It is noteworthy that, although loss of sulphur dioxide from thiosulphonates has occasionally been reported (see, for example, W. L. F. Armarego and E. E. Turner, J. Chem. Soc., 1956, 1665; A. Padwa and R. Gruber, J.Org. Chem., 35, 1970, 1781), this reaction has hardly any precedent so far as yields and mildness of operative conditions are concerned and for the first time it has been applied in the synthesis of p-lactam compounds. The present invention also provides routes to obtain the required compounds of formula II possessing the (5R) configuration.
According to the invention, the compounds of the general formula Il are prepared by either of the routes shown in the following reaction scheme wherein: R1,R2 and Y are as defiend above, Z represents i) a group of the formula SR7 wherein R7 represents an alkyl group having from 1 to 8 carbon atoms, a phenyl or tolyl group, or, preferably, a heterocyclic group, especially a 2-benzothiazolylthio or 1 -methyl-tetrazol-5-yl-thio group, ii) a group of the formula SCOUR, wherein R8 represents an optionally substituted lower alkyl group, preferably a methyl group, iii) a group of the formula
wherein R9 and R10 independently represent lower alkyl or aryl groups, or together with the dicarboxyamino group form a heterocyclic ring, preferably a succinimido or phthalimido group, or iv) a group of the formula
wherein R7 represents an optionally substituted lower alkyl or aryl group, preferably a methyl, phenyl or p-tolyl group; and L represents a halogen atom, an alkane sulphonyloxy group or an arene sulphonyloxy group, preferably a methanesulphonyloxy group.
Compounds of the general formula IV, which are used as starting materials, are known compounds or can be obtained from known compounds by per se known procedures; the preparation of some representative entities is described in the Examples.
The compound of the general formula IV is first ozonolysed to give a compound of the general formula VI. The hydroxy group is then converted into a group Land the resultant compound of the general formula VIII is cyclised to give a compound of the general formula ll in which Y represents a hydrogen atom. If desired, the methyl group may then be halogenated to give a compound of the general formula II in which Y represents a halogen atom.
In an alternative process, the compound of the general formula IV may first be halogenated by methods known per se (allyl, ene-type, or electrochemical halogenation, see Tetrahedron Letters, 1980, 71 and 351; 1981, 3193; 1982, 2187). The resultant compound of the general formula V is then ozonolysed; the hydroxy group of the resultant compound of the general formula VII is then transformed into a group Land the resultant compound of the general formula IX is cyclised to give a compound of the general formula II.
The group Yin the compounds of the general formulae V, VII, IX and II may, if it represents a halogen atom, be optionally transformed into any of the other groups, which Y may represent except a hydrogen atom. According to a preferred feature of the invention, this transformation is preferably carried out on the compounds of the general formula II.
The transformation into a group L of the hydroxy group in the enol VI or VEIL, which may be in equilibrium with the corresponding keto-tautomer, is preferably a mesylation. We have surprisingly found that, when this reaction is carried out in tetrahydrofuran instead of the ubiquitously used halogenated hydrocarbons, mesylates IX or VIII having Z alkene geometry, which are the most suitable ones for the subsequent cyclization, are almost exclusively obtained (similar transformation performed in dichloromethane usually affords a 1:1 mixture of E, Z isomers: see T. W. Doyle et al., Can. J. Chem., 1977, 55, 2873; M. J. Pearson, J. Chem. Soc., Chem. Comm. 1981, 947; P. C. Cherry et al., J. Chem.
Soc., Chem. Comm. 1979 663. Cyclisation of VIII or IX may be carried out in a single step, by reaction with a sulphide or hydrosulphide, such as Na2S, NaHS, Bu4NHS, or with H2S in the presence of a base such as triethylamine or pyridine. The cyclisation of IX or Villi wherein Z represents a group other than SR7 offers the clear advantage of releasing easily separable, usually water soluble by-products ZH (e.g.
phenylsulphinic acid, succinimide), instead of by products R3SH (e.g. mercaptobenzthiazole) which usually require chromatographic separation or precipitation as heavy metal salts (Ag+, Pb2+).
Against any reasonable expectation, which would rule out the possibility of halogenating the 3methyl group of the compounds II (Y=H) owing to the presence of the disulphide moiety, we have found a method to effect such transformation in high yield. We can thus obtain the compounds II (Y=halogen), which are invaluable intermediates for the synthesis of highly active penem antibiotics I.
A preferred halogenating reagent for such transformation is N-bromosuccinimide, which is best used in the presence of a radical initiator, such as azobisisobutyronitrile or benzoyl peroxide in the presence of acid scavengers, such as epoxides (e.g. propylene oxide), alkaline-earth oxides (e.g. calcium oxide), or molecular sieves, in solvents such as benzene, carbon tetrachloride or ethyl formate at a temperature ranging from 200Cto 1300C.
The compounds II (Y=halogen) can be converted into compounds II (Y=an organic group) by reactions known per se; e.g.
1) a compound II (Y=Br or Cl) can be converted into a compound II (Y=free or protected OH) by mild alkaline hydrolysis, or by reaction with cuprous oxide/dimethylsulphoxide/water or by reaction with a salt of a strong inorganic acid, e.g. a nitrate or a perchlorate, thus obtaining a labile ester with the said inorganic acid, which ester may be hydrolyzed, subsequently or in the same reaction medium, to the desired parent alcohol.Preferred salts of this type are AgNO3, AgClO4, NaNO3; 2) a compound II (Y=Br or Cl) can be converted into a compound II (Y=an unsubstituted or Nalkyl substituted carbamoyloxy group) by conversion into a compound II (Y=OH) as described above followed by reaction with a suitable isocyanate; for example, trichloroacetyl isocyanate is a preferred reagent for obtaining compounds II (Y=OCONH2), following deprotection of the trichloroacetyl moiety on the first formed urethane adduct; 3) a compound II (Y=Br or Cl) can be converted into a compound II (Y=acyloxy) by reaction with a suitable salt of the corresponding carboxylic acid in a suitable solvent or under phase-transfer catalysis: or by conversion into a compound II (Y=OH) followed by conventional acylation; 4) a compound II (Y=Br or Cl) can be converted into a compound II (Y=S-Het) by reaction with the corresponding HS-Het in the presence of a base, or with a preformed salt of HS-Het with a base, in a suitable solvent, such as tetrahydrofuran, acetone, acetonitrile, or dimethylformamide. A suitable base is triethylamine; a suitable preformed salt is a sodium salt, e.g. sodium 1 -methyl-1 ,2,3,4-tetrazol- 5-yl-mercaptide.
Owing to the pronounced propensity of 3-hydroxymethyl-2-thiacephem-4-carboxylates to lactonize, it is preferable that in the process 1) described above R2 represents a somewhat bulky group, forming with the linked carboxy moiety an ester possessing a relative inertness towards nucleophilic attack by the neighbouring hydroxy group, e.g. a tert-butyl ester. Alternatively, it may be convenient to deprotect the hydroxy group from a protected form thereof after the ring-contraction step to the corresponding penem I, since 2-hydroxymethylpenemcarboxylates do not lactonize easily. For example, a compound II (Y=Br) may be converted into a compound II (Y=ONO2), which may easily be isolated, purified if necessary, and desulphurized to the corresponding penem I whose reductive hydrolysis (e.g.
Zn/CH3COOH) affords without problems the free hydroxy derivative.
Owing to the different stability of the penem and 2-thiacephem nucleus towards the conditions required for -COOR2 ester hydrolysis, a distinct advantage of the invention is that ester hydrolyses not compatible with a penem can be performed on the 2-thiacephem precursor, and the ring contraction may be performed on the free acid, or on a salt with an organic or inorganic base, or on a different labile ester, which can be prepared in situ, if desired; e.g. a trimethylsilyl, t-butyldimethylsilyl, or t butyldiphenylsilyl ester.
The following Examples illustrate the invention. The abbreviations Me, But, Ph, Ms, pNB, THF, EtOAc, DMSO, MeCN, stand respectively for methyl, t-butyl, phenyl, methanesulphonyl, p-nitrobenzyl, tetrahydrofuran, ethyl acetate, dimethylsulphoxide and acetonitrile. NMR spectra were taken either on a Hitachi-Perkin Elmer 60 MHz apparatus, or on a Brucker 90 MHz; separation of inner lines of AB quartets are referred to spectra taken on the latter.
Example 1 Diphenylmethyl 6,6-dibromopenicillanate 90 g of 6,6-dibromopenicillanic acid in 450 ml of acetonitrile was treated with a solution of 49 g of diphenyldiazomethane in 150 ml of acetonitrile. After 1 hour at 200C the formed solid was collected by filtration and washed with small portions of cold diethyl ether, thus obtained 116 g of the title product. A second crop(9 g) was obtained by evaporation of the mother liquors and trituration with diethyl ether. The overall yield was 95%.
Analytical sample was obtained by crystallization from chloroform; mp 1 57-1 580C; Vmax (CHCI3 film) 1800, 1750 cm-1; S(CDCI3) 1.24 and 1.58 (each 3H, s, CMe2), 4.61(1 H, s, N.CH.CO), 5.80 ( 1 H, s, N.CH.S), 6.91 H, S. OCH), and 7.30 ppm (1 OH, s. Ar).
Found: C, 47.80; H, 3.63; N, 2.64; S, 5.95; Br, 30.49%. C2,H,9Br2NO3S requires C, 48.02; H, 3.64; N, 2.67; S, 6.10; Br, 30.43%.
Example 2 t-Butyl 6,6-dibromopenicillanate Method A 100 g of 6,6-dibromopenicillanic acid in 1 litre of diethyl ether at 0 C was sequentially treated with 37 ml of triethylamine and 56 g of phosphorus pentachloride. After 1 hour stirring, the reaction mixture was evaporated under vacuum (dry benzene added and removed). The crude acyl chloride was dissolved in 200 ml of dichloromethane and stirred for 24 hours with 500 ml of t-butanol in the presence of 50 g of calcium carbonate. The suspended salts were then filtered off, and the solution was washed with aqueous sodium bicarbonate solution (some unreacted starting material could be recovered by back-extraction of the acidified aqueous washings), decoloured with charcoal and evaporated to afford the title product, which was then crystallized from diisopropyl ether.Yield 69 g (60%); mp 120-121 0C, "rnax (CHCI3 film) 1800 and 1740cm-t;S(CDCI3) 1.98 (15H, S, But and CH3), 2.05 (3H, s, CH3), 4.38 ( 1 H, S, N.CH.CO) and 5.70 ppm (1 H, s, N.CH.S).
Method B 15 g of 6,6-dibromopenicillanic acid in 300 ml of dichloromethane was stirred overnight with 25 g of O-t-butyl-N,N-diisopropyl-isourea. The reaction mixture was filtered and the solution washed with aqueous sodium bicarbonate solution. Crystallization of the product from diisopropyl ether gave the title compound, 8 g (47%).
Example 3 Diphenylmethyl 6-bromo-6/3-( 1 R-hydroxyethyl)-penicillanate 120 g of diphenylmethyl 6,6-dibromopenicillanate, prepared as described in Example 1, in 900 ml of dry distilled THF under nitrogen at -750C was treated with 1 molar equivalent of a solution of ethylmagnesium bromide in diethyl ether. After 20 min at -750C, 25.7 ml of acetaldehyde was added and the mixture was further stirred for 20 min at -75 C. After quenching with 400 ml of saturated aqueous ammonium chloride, partition between water and diethyl ether followed by removal of the solvent left the crude product.This was fractionated by silica gel chromatography (benzene:ethyl acetate) to afford the title compound, 67 g (60%), as a foam, crystallizable (diisopropyl ether) to a solid, mp 65-700C; PmaX (film) 3450, 1785 and 1740 cm-'; d(CDCI3) 1.22 and 1.60 (each 3H, s, CMe2), 1.29 (3H, d, J=6Hz, CH3.CH), 2.90 (1 H, d, OH), 4.17 (1 H, m, CH3.CH.OH), 4.58 (1 H, s, N.CH.CO), 5.49 (1H, s, N.CH.S), 6.90 (1H, s, OCHPh2) and 7.3 ppm (1 OH, s. Ar).
Using t-butyl-6,6-dibromopenicillanate, prepared as described in Example 2, and proceeding similarly, there were obtained t-butyl 6&alpha;-bromo-6ss-(1R-hydroxyethyl)-penicillanate in 65% yield after crystallization from diisopropyl ether: hexane; m.p. 93-950C with decomposition; S(CDCI3) 1.28 (3H, d, J=6Hz, CH3.CH), 1.54 (12H, s, But and CH3), 1.65 (3H, s, CH3), 2.65 (1 H, s, CH.OH),4.25 (1 H, m, CH3.CH(OH).CH), 4.40 (1 H, s, N-CH.CO) and 5.51 ppm (1 H, s, N.CH.S).
Example 4 Diphenylmethyl 6-( 1 R-hydroxyethyl)-penicillanate-1 -oxide 52 g of diphenylmethyl 6-bromo-6,B-(1 R-hydroxyethyl)-penicillanate, prepared as described in Example 3, in 400 ml of 95% ethanol was hydrogenated at 20700 pascals in the presence of 25 g of 10% by weight palladium-on-calcium carbonate and 11 g of calcium carbonate. The reaction mixture was filtered and evaporated to afford a residue which was partitioned between brine and dichloromethane. Removal of the solvent left crude diphenylmethyl 6a-( 1 R-hydroxyethyl)penicillanate, which was oxidized with 17 g of 85% MCPBA in 500 ml of chloroform at 0-5 C for 1 hour.The filtered solution was then washed with aqueous sodium bicarbonate solution and the solvent removed to leave 40 g (88%) of the crude title product as a foam, which can be used as such or purified by silica gel chromatography; Vmax (CHCl3 film) 1790 and 1750 cm-'; #(CDCl3) 0.94 and 1.67 (each 3H, s, CMe2), 1.37 (3H, d, J=6Hz), 3.55 ( 1 H, dd, J=2 and 6.5Hz, CH.CH.CH), 4.25 (1H, m, CH3.CH(OH).CH), 4.64 (1H, s, N.CH.CO), 4.98 (1H, d, J=2Hz, CH.CH.S), 6.98 (1H, s, OCHPh2) and 7.30 ppm (10H,s,Ar).
Using a similar procedure but starting from t-butyl 6-bromo-6ss-(1 R-hydroxyethyl)-penicillanate, prepared as described in Example 3, there was obtained t-butyl 6&alpha;-(1R-hydroxyethyl)-penicillanate-1- oxide: yield 75%: #max (film) 3440, 1785 and 1740 cm-'.
Example 5 Diphenyl methyl 6-(1 R-t-butyldimethylsilyloxyethyl)penicillanate-1 -oxide 40 g of crude diphenylmethyl 6&alpha;-(1 R-hydroxyethyl)-penicillanate-1-oxide, prepared as described in Example 4, was dissolved in 350 ml of DMF and stirred for 3 hours at 50-550C in the presence of 18.5 g of imidazole and 27 g of t-butyldimethylsilyl chloride. The reaction mixture was partitioned between diethyl ether and brine and the organic layer washed several times with water.Evaporation of the solvent and silica gel chromatography afforded the title product; yield 22 g; PmaX (CHCI3 film) 1790 and 1755 cm-1: #(CDCl3) 0.06 (6H, s, SiMe2), 0.88 (1 3H, s, But and CH3), 1.3 (3H, d, J=6Hz, CH3.CH), 1.7 (3H, s, CH3), 3.4 ( 1 H, dd, J=2 and 4.5Hz, CH.CH.CH), 4.40 ( 1 H, m, CH3-CH.CH)4.55(1H,s, N.CH.CO), 4.88 (1 H, d, J=2, CH.CH.S), 6.9 (1 H,SOCHPh2), and 7.25 ppm (1 OH, s. Ar).
By using a similar procedure, but starting from t-butyl 6&alpha;-(1 R-hydroxyethyl)-penicillanate- 1 - oxide, prepared as described in Example 4, there was obtained t-butyl 6-(1R-t-hutyldimethylsilyloxy- ethyl)-penicillanate- 1-oxide in overall yield 55% from the 6-bromoprecursor; #max (CHCI3 film) 1785 and 1750 cm-1; S(CDCI3) 0.06 (6H, s, SiMe2), 0.88 (9H, s, SiBut), 1.25 and 1.66 (each 3H, s, CMe2), 1.28 (3H, d, J=6Hz, CH3.CH), 1.45 (9H, s, OBut), 3.5 (1 H, dd, j=2 and 5Hz, CH.CH.CH), 4.4 (1 H, s, N.CH.CO), 4.5 (1 H, m, CH3.CH.CH) and 4.9 ppm (1 H, d, J=2Hz, CH.CH.S).
Example 6 Diphenyl 6a-( I R-p-nitrobenzyloxycarbonyloxyethyl)-penicillate-1 -oxide Diphenylmethyl 6a-(1 R-hydroxyethyl)-penicillanate-1 -oxide, prepared as described in Example 4, was acylated with p-nitrobenzylchiorocarbonate by using N, N-dimethylaminopyridine as a base and ethanol-free dichloromethane as solvent, according to a general method, thus obtaining the title product as a foam;; #(CDCl3) 0.96 and 1.70 (each 3H, s, CMe2), 1.52 (3H, d, J=6Hz, CH3.CH), 3.83 ( 1 H, dd, J=2 and 6Hz, CH.CH.CH), 4.66 (1 H, s, N.CH.CO), 4.99 (1 H, d, J=2Hz, CH.CH.S), 5.28 (2H, s, OCH2Ph), 5.35 (1H, m, CH3.CH.CH), 7.01 (1H,s,OCHPh2), 7.40 (10H, mAr), 7.55 and 8.26 ppm (each 2H, d, J=8Hz, Ar).
Following the same experimental procedure, there was obtained t-butyl 6a-(lR-p-nftrobenzyioxy- carbonyloxyethyl)-penicillanate- 1-oxide.
Following similar experimental procedures, but using trichloroethylchlorocarbonate instead of pnitrobenzylchlorocarbonate, there were also obtained: t-butyl-6&alpha;-( 1R-trichloroethyloxycarbonyloxyethyl)-penicillanate- 1-oxide diphenylmethyl 6a-( l R-trichloroethyloxycarbonyloxyethyl)-penicillanate- 1-oxide.
Example 7 3S-( 1 R-hydroxyethyl)-4R-benzthiazolyldithio-1 -(1 -methoxycarbonyl-2-methyl-1 -prop-2-enyl)azetidin-2-one A mixture of 5 g of methyl 6a-(1 R-hydroxyethyl)-penicillanate-1 -oxide and 3.04 g of 2mercaptobenzthiazole was refluxed for 2 hours in dry toluene. The solvent was removed in vacuo and the crude product used as such for the next step.
Using similar procedures, there were obtained: 3S-(1R-t-butyldimethylsilyloxyethyl)-4R-benzthiazolyldithio- 1 -(1 -methoxycarbonyl-2-methyl- 1 - prop-2-enyl)-azetidin-2-one, starting from methyl 6&alpha;-(1 R-t-butyldimethylsilyloxyethyl)-penicillanate- 1-oxide, and prolonging the reaction time up to 6 hours;; Vmax (CHCI3 film) 1770 and 1744 cm-1, #(CDCl3) 0.02 and 0.04 (each 3H, s, SiMe2), 0.84 (9H, s, SiBut), 1.23 (3H, d, J=6Hz, CH3.CH),1.91(3H, s, =C.CH3), 3.38 (1 H, dd, J=2 and 3.5Hz, CH.CH.CH), 3.69 (3H, s, OCH3), 4.23 (1 H, m, CH3.CH.CH), 4.82 (1H, s, N.CH.CO), 5.07 (2H, m, CH2=C), 5.42 (1H, d, J=2Hz, CH.CH.S) and 7.2-7.9 ppm (4H, m, Ar); 3S-(1, R-hydroxyethyl)-4R-benzthiazolyldithio- 1 -r1 -diphenylmethoxycarbonyl-2-methyl- 1 -prop-2- enyl)-azetidin-2-one, starting from diphenylmethyl 6a-( 1 R-hydroxyethyl)-penicillanate-1-oxide; ; Amax (CHCl3 film) 3400, 1 765 and 1740 cm-1; #(CDCl3) 1.22 (3H, d, J=6Hz, CH3.CH), 1.60 (3H, s, -C.CH3), 2.78 (1 H, Br s, OH), 3.42 (1 H, dd, J=2 and 6Hz, CH.CH.CH), 4.18 (1 H, m, CH3.CHOH.CH), 4.93 (1 H, s, N.CH.CO), 4.90-5.10 (2H, m, CH2=C), 5.38 (1 H, d, J=2Hz, CH.CH.S), 6.89 (1 H, s, OCHPh2) and 7.15-7.90 ppm (14H, m.Ar); 3S-(1 R-t-butyldimethylsilyloxyethylJ-4R-benzothiazolyldithio- 1 -(1 -t-butoxycarbonyl-2-methyl- 1 - prop-2-enyl)-azetidin-2-one, starting from t-butyl 6&alpha;-(1R-t-butyldimethylsilyloxyethyl)-penicillanate-1- oxide; reaction time 6 hours; S(CDCI3) 0.06 (6H, s, SiMe2), 0.9 (9H, s, SiBut), 1.26 (3H, d, J=6Hz, CH3.CH), 1.48 (9H, s, OBut), 1.95 (3H, s, =C.CH3), 3.40 (1H, dd, J=2 and 4Hz, CH.CH.CH), 4.20 ( 1 H, m, CH3.CH.CH), 4.71 (1H, s, N.CH.CO), 5.1 2H, brs, CH2=C), 5.42 (1H, d, J=2Hz, CH.CH.S) and 7.2-7.9 ppm (4H, m, Ar); 3S-( 1 R-t-butyldimethylsllyloxyethyl)-4R-benzthiazolyldithio- 1-(1-diphenylmethoxycarbonyl-2- methyl-1-prop-2-enyl)-azetidin-2-one, t'max (fiim) 1722 and 1743 cm-1;; #(CDCl3) 0.05 (6H, s, SiMe2), 0.80 (9H, s, SiBut), 1.29 (3H, d, J=6Hz, CH3.CH), 1.95 (3H, s, =C.CH3), 3.45 (1 H, dd, J=2 and 4Hz, CH.CH.CH), 4.26 (1 H, m, CH3.CH.CH), 4.95 (1 H, s, N.CH.CO), 5.08 (2H, ABq, separation of inner lines 5Hz, CH2=C), 5.55 (1 H, d, J=2Hz, CH.CH.S), 6.93 (1 H, s, OCHPh2) and 7.1-8.0 ppm (1 4H, m, Ar); 3S-(1R-trichloroethoxycarbonyloxyethyl)-4R-benzthiazolyldithio-1-(1-methoxycarbonyl-2- methyl- 1 -prop-2-enyl)-azetidin-2-one, starting from methyl 6-( 1 R-trichloro ethoxycarbonyloxyethyl)-penicillanate-1-oxide:: #max (CHCl3) 1775 and 1745 cm-1; #(CDCl3) 1.48 (3H, d, J=6Hz, CH3.CH), 1.91 (3H, s, =C.CH3), 3.69 (3H,s, OCH2), 3.70(1 H, dd, CH.CH.CH), 4.68 (s, 2H, OCH2), 4.76 (1 H, s, N.CH.CO), 5.03-5.30 (2H, m, CH2=C), 5.23 (1 H, m, CH3.CH.CH), 5.32 (1 H, d, J=2Hz, CH.CH.S) and 7.10-7.96 ppm (4H, m, Ar); and, in a likewise fashion, starting from the corresponding t-butyl and diphenyl methyl penicillanates, 3S-( 1R-trichloroethoxycarbonyloxyethyl)-4R-benzthiazolyldithio- 1 -r 1 -t-butoxycarbonyl-2methyl- 1 -prop-2-enyl)-azetidin-2-one;; 3S-( 1 R-trichloroethoxycarbonyloxyethyl)-4R-benzthiazolyldfth!o- 1 -(1 -diphenylmethoxycarbonyl2-methyl- 1 -prop-2-enyl)-azetidin-2-one; and starting from methyl 6p-(1 R-t-butyldimethylsilyloxyethyl)-penicillanate-1 -oxide, 3R-(1R-t-butyldimethylsilyloxyethyl)-4R-benzthiazolyldithio- 1 -(1 -methoxycarbonyl-2-methyl-1- prop-2-enyl)-azetidin-2-one.
Example 8 3S-( 1 R-hydroxyethyl)-4R-benzthiazolyldithio-1 -(I -methoxycarbonyl-2-hydroxy-1 -prop-1-enyl)- azetidin-2-one The crude 3 S-( 1 R-hydroxyethyl )-4R-benzthiazolyldithio-1-(1-methoxycarbonyl-2-methyl-1-prop- 2-enyl)azetidin-2-one obtained in Example 7 was dissolved in 300 ml of dry dichloromethane and treated with a stream of ozone at -700C until TLC showed that all the starting material had reacted.
The solution was purged with nitrogen and then 10 g of sodium metabisulphite was added at -300C.
The mixture was allowed to rise to room temperature under vigorous stirring, and then filtered. The solution was washed with 4% aqueous sodium bicarbonate solution, dried over anhydrous sodium sulphate and evaporated. The residue was taken up in diethyl ether, the undissolved matter was filtered off and the solution was evaporated to give the crude title product. An aliquot was purified by flash chromatography over silica gel (ethyl acetate:cyclohexane as eluant); b(CDCI3) 1.35 (3H, d, J=7Hz, CH3.CH), 2.1 1 (3H, s, CH3), 2.75 ( 1 H, Br s, OH), 3.44 ( 1 H, dd, J=2.0 and 5.0Hz, CH.CH.CH), 3.79 (3H, s, OCH3), 4.26 (1 H, m, CH3.CH.CH), 5.29 (1 H, d, J=2.0Hz, CH.CH.S) and 7.25-7.95 ppm (4H, m. Ar).
By using a similar procedure, there were obtained: 35(1 R-t-butyld!methylsllyloxyethyl)-4R-benzth!azolyldfthio- 1-(1-methoxycarbonyl-2-hydroxy-1- prop-1-enyl)-azetidin-2-one, starting from crude 3S-( 1 R-t-butyldimethylsilyloxyethyl)-4R benzthiazolyldithio-1 -(1 -methoxycarbonyl-2-methyl-1 -prop-2-enyl)-azetidin-2-one; #max (film) 3350, 1770 and 1660 cm-1; #(CDCl3) 0.05 and 0.07 (6H, each s, SiMe2), 0.87 (9H, s, SiBut), 1.27 (3H, d, J=6.5Hz, CH3.CH), 2.07 (3H, s, =C.CH3), 3.33 (1 H, dd, J=2.2 and 4.2Hz, CH.CH.CH), 3.74 (3H, s, OCH3), 4.26 (1 H, m, CH3.CH.CH), 5.36 (1 H, d, J=2.2Hz, CH.CH.S), 7.2-7.9 (4H, m, Ar) and 12.37 ppm (1H, burs, OH);; 3R-(1R-t-butyldimethylsilyloxyethyl)-4R-benzthiazolyldithio-1-(1-methoxycarbonyl-2-hydroxy-1- prop- 1 -enyl)-azetidin-2-one, starting from 3 R-( 1 R-t-butyldi methylsilyloxyethyl)-4R-benzthiazolyldithio- 1 -(1 -methoxycarbonyl-2-methyl-1 -prop-2-enyl)-azetidin-2-one; Vmax (film) 3200, 1773, 1710, 1665 and 1620 cm-1. S(CDCI3) 0.20 (6H, s, SiMe2), 0.94 (9H, s, SiBut), 1.52 (3H, d, J=6Hz, CH3.CH), 2.17 (3H, br s, =C.CH3), 3.6-3.7 (4H, s+dd, OCH3 and CH.CH.CH), 4.4 (1 H, m, CH3.CH.CH),5.25(1H,d, CH.CH.S) and 7.3-7.9 ppm (4H, m, Ar);; 3S-(1R-hydroxyethyl)-4R-benzthiazolyldithio- 1-(1 -diphenylmethoxycarbonyl-2-hydroxy-1-prop 1 -enyl)-azetidin-2-one, starting from crude 3 S-(1 R-hydroxyethyl)-4R-benzthiazolyldithio- 1 -(1 diphenylmethoxycarbonyl-2-methyl-1 -prop-2-enyl)-2-azetidin-2-one; VmaX (CHCl3 film) 3400, 1770, 1730 and 1650 cm-'; 3S-( R-t-butyidimethylsilyloxyethyl)-4R-benzthiazolyidithio- 1 -f 1 -diphenylmethoxycarbonyl-2hydroxy- 1-prop- 1 -enyl)-azetidin-2-one, starting from crude 3 S-( 1 R-t-butyldimethylsilyloxyethyl)-4R- benzthiazolyldithio- 1 -(1 -diphenylmethoxycarbonyl-2-methyl-1 -prop-2-enyl)-azetidin-2-one; ; Vmax (CHCl3 film) 3400, 1775, 1735, 1700 sh, 1655 and 1610 cm-1; #(CDCl3) 0.06 (6H, s, SiMe2), 0.82 (9H, s, But), 1.26 (3H, d, J=6Hz, CH3.CH), 2.08 (3H, s, =C.CH3), 3.33 (1 H, dd, J=3 and 5.5 Hz, CH.CH.CH), 4.18 (1H, m, CH3.CH.CH), 5.22 (1 H, d, J=2Hz, CH.CH.S), 6.86 (1 H, s, OCHPh2) and 7.2- 7.9 ppm (14H, m, Ar); and 3 S-( 1R-trichloroethoxycarbonyloxyethyl)-4R-benzthiazolyidithio- 1 -(1-methoxycarbonyl-2 - hydroxy-1-prop-1-enyl)-azetidin-2-one; #(CDCl3) 1.50 (3H, d,J=6Hz, CH3.CH), 2.14 (3H, s =C.CH3), 3.67 (1 H, dd, J=2.2 and 5.5Hz, CH.CH.CH), 3.82 (3H, s, OCH3), 4.62 (2H, ABq, J=1 2Hz, separation of inner lines 2Hz, OCH2), 5.10-5.40 (2H, m, CH3.CH.CH and CH.CH.S), 7.20-8.00 (4H, m, Ar) and 12.40 ppm (1H, brs, OH); and in likewise fashion, starting from the corresponding t-butyl and diphenylmethyl ester, 3S-(1 R-trichloroethoxycarbonyloxyethyl)-4R-benzthiazolyidithio- 1-(1 -t-butoxycarbonyl-2 hydroxy-i -prop-i -enyl)-azetidin-2-one; 3S-( 1 R-trichloroethoxycarbonyloxyethyl)-4R-benzthiazolyldithio- 1 -(1 -diphenylmethoxycarbonyl2-hydroxy- 1-prop- 1-enyl)-azetidin-2-one;; and 3S-(1R-t-butyldimethylsilyloxyethyl)-4R-benzthiazolyidithio- 1-(1-t-butoxycarbonyl-2-hydroxy-1- prop-1 -enyl)-azetidin-2-one.
Example 9 3S-( 1 R-hydroxyethyl)-4R-benzthiazolyldithio-1 -(I -methoxycarbonyl-2-methylsulphonyloxy-1- prop-1-enyl)-azetidin-2-one A solution of 130 mg (0.03 mmol) of 3S-(1 R-hydroxyethyl)-4R-benzthiazolyldithio-1-(1- methoxycarbonyl-2-hydroxy-1 -prop-1 -enyl)-azetidin-2-one, prepared as described in Example 8, in 8 ml of an hydros dichloromethane was sequentially treated at -400C with 0.043 ml (0.3 mmol) of triethylamine and 0.024 ml (0.31 mmol) of methanesulphonyl chloride. The reaction was quenched after 5 minutes with cold 2% aqueous sodium bicarbonate solution. Removal of the solvent from the organic layer gave the crude title product (quantitative yield), which was used as such for the next step.
By following the same experimental procedure, there was obtained: 3S-(1R-t-butyldimethylsilyloxyethyl)-4R-benzthiazolyidithio-1-(1-methoxycarbonyl-2methylsulphonyloxy-1-prop-1-enyl)-azetidin-2-one, starting from 3S-(1R-t-butyldimethylsilyloxy- ethyl)-4R-benzthiazolyldithio-1-(1-methoxycarbonyl-2-hydroxy-1-prop-1-enyl)-azetidin-2-one; an aliquot of this product was purifed by flash chromatography (silica gel; ethyl acetate-cyclohexane as eluant) to afford the pure title compound as a 1:1 mixture of E and Z isomers; PmaX (film) 1885, 1730, 1363 and 1165 cm (CDCI3) 0.05 and 0.10 (each 3H, s, SiMe2) 0.88 (9H, s, SiBut), 1.29 (3H, d, J=6.5Hz, CH3.CH), 2.20 and 2.53 (3H, each s, =C.CH3), 3.18 and 3.29 (3H, each s, SO2CH3), 3.42 (1H, m, CH.CHCH, 3.71 and 3.78 (3H, each s, OCH3), 4.30 (1H, m, CH3.CH.CH), 5.59 and 5.64 (1H, each d, J=2Hz, CH.CH.S) and 7.12-7.96 ppm (4H, m, Ar).
When tetrahydrofuran was used instead of dichioromethane as a solvent, the formation of the undesired E isomer was almost suppressed, and the pure Z isomer thus collected; #(CDCl3) 0.05 (6H, s, SiMe2), 0.88 (9H, s, SiBut), 1.29 (3H, d, J=6.5Hz, CH3OH), 2.53 (3H, s, =C.CH3), 3.29 (3H, s, SO2CH3), 3.42 (1 H, dd, J=2 and 5Hz, CH.CH.CH), 3.71 (3H, s, OCH3), 4.30 ( 1 H, m, CH3.CH.CH), 5.59 (1 H, d, J=2Hz, CH.CH.S) and 7.12-7.95 ppm (4H, m. Ar).
By following this last procedure (tetrahydrofuran as a solvent in the mesylation step), there were obtained: 3R-( 1 R-t-butyidimethylsilyloxyethyl)-4R-benzthiazolyidithio- 1 -[1 -methoxycarbonyl-2-methylsulphonyloxy- 1-prop-1 -(Z)-enyl]-azetidin-2-one, starting from 3R-( 1 R-t-butyldimethylsilyloxyethyl)-4R benzthiazolyldithio-1 -(1 -methoxycarbonyl-2-hydroxy-1 -prop-1 -enyl)-azetidin-2-one; Vmax (CHCI3 film) 1775, 1735, 1365 and 1165 cm-';; ot(CDCi3) 0.18 (6H, s, SiMe2), 0.88 (9H, s, SiBut), 1.42 (3H, d, J=6.5Hz, CH3.CH), 2.33 (3H, s, =C.CH3), 3.05 (3H, s, SO2CH3), 3.45 (3H, s, OCH3), 3.62 (1H, dd, CH.CH.CH), 4.3 (1 H, m, CH3.CH.CH), 5.40 (1 H, d, J=5Hz, CH.CH.S) and 7.15-7.85 ppm (4H, m, Ar); 3S-r1 R-hydroxyethyl)-4R-benzthiazolyldithio- 1-[1 -diphenylmethoxycarbonyl-2-methyl sulphonyloxy- 1-prop-i -(Z)-enyl]-azetidin-2-one, starting from 3S-( 1 R-hydroxyethyl)-4R-benzthiazolyl dithio-1-(1-diphenylmethoxycarbonyl-2-hydroxy-1-prop-1-enyl)-azetidin-2-one;##max (film) 3400, 1775, 1730, 1365 and 1170 cm-1;; # (CDCl3) 1.22 (3H, d, J=6.5Hz, CH3.CH), 2.43 (3H, s, =C.CH3), 3.13 (3H, s, SO2CH3), 3.35 ( 1 H, dd, J=2.5 and 4Hz, CH.CH.CH), 4.1(1 H, m, CH3.CH.CH), 5.40 ( 1 H, d, J=2.5Hz, CH.CH.S), 6.85 (1 H, s, OCHPh2) and 7.1-7.9 ppm (14H, m, Ar); 3S-( 1 R-t-butyldimethylsllyloxyethyl)-4R-benzthiazolyldfthio- 1 -[1 -diphenylmethoxycarbonyl-2 (Z)-methylsulphonyoxy- 1-prop- 1 -enyl]-azetidin-2-one, starting from 3S-(1 R-t-butyldimethylsilyloxyethyl)-4R-benzthiazolyldithio- 1 -(1 -diphenyl methoxycarbonyl-2-hydroxy- 1-prop- 1 -enyl)-azetidin-2one;; PmaX (CHCI3 film) 1775, 1725, 1370 and 1175 cm-'; o(CDCI3) 0.1 (6H, s, SiMe2), 0.9 (9H, s, SiBut), 1.28 (3H, d, J=6Hz, CH3.CH), 2.5 (3H, s, =C.CH3), 3.25 (3H, s, SO2CH3),3.35 (1 H, dd, J=2.5 and 5Hz, CH.CH.CH), 4.20 (1 H, m, CH3.CH.CH), 5.50 (1 H, d, J=2.5Hz, CH.CH.S), 6.9 (1 H, s, OCHPh2) and 7.1-7.9 ppm (14H, m, Ar); 3S-( 1 R-t-butyidimethylsilyloxyethyl)-4R-benzthiazolyidithio- 1-[1-t-butoxycarbonyl-2-(Z)-methyl- sulphonyloxy- 1-prop- 1 -enyl]-azetidin-2-one, starting from 3S-(1 R-t-butyldimethylsilyloxyethyl)-4Rbenzthiazolyldithio-1 -(1 -t-butoxycarbonyl-2-hydroxy-1 -prop-1 -enyl)-azetidin-2-one; ; #max (film) 1 773, 1710, 1370 and 1165 cm-1; #(CDCl3) 0.06 (6H, s, SiMe2), 0.87 (9H, s, SiBut), 1.25 (3H, d, J=6Hz, CH3.CH), 1.49 (9H, si, OBut), 2.45 (3H, s, =C.CH3), 3.25 (3H, s, SO2CH3), 3.35 (1 H, dd, J=2.5 and 5Hz), 4.3 (1 H, m, CH3.CH.CH), 5.60 (1 H, d, J=2.5Hz, CH.CH.S) and 7.1-7.9 ppm (4H, mAr);; and 3 S-( I R-trichloroethoxycarbonyloxyethyl)-4R-benzthiazolyldfthio- 1-[1 -methoxycarbonyl-2- methylsulphonyloxy- 1-prop-1 (Z)-enyl]-azetidin-2-one, starting from 3S-( 1 R-trichloroethoxyca carbonyloxyethyl)-4R-benzthiazolyldithio-1-(1-methoxycarbonyl-2-hydroxy- 1-prop- 1 -enyl)-azetidi n-2one; ,'max (CHCI3 film) 1780, 1755 sh, 1730, 1380, 1250 and 1167 cm-1; #(CDCl3) 1.48 (3H, d, J=6Hz, CH3.CH), 2.52 (3H, s, =C.CH3), 3.25 (3H, s, SO2CH3), 3.72 (4H, s+dd, OCH3 and CH.CH.CH), 4.68, (2H,s, OCH2), 5.2 (1H, m,Ch3.CH), 5.47 (1H,d,J=2.5Hz,CH.CHS) and 7.1-7.9ppm (4H, m,Ar);; and likewise, starting from the corresponding t-butyl and diphenylmethyl esters, there was obtained: 3S-( 1 R-trichloroethoxycarbonyloxyethyl)-4R-benzthiazolyidithio- 1-[1 -t-butoxycarbonyl-2methylsulphonyloxy- 1-prop-i (Z)-enyl]-azetidin-2-one; and 3S-( 1 R-trichloroe thoxycarbonyloxyethyl)-4R-benzthiazolyldithio- 1 -[1 -diphenylmethoxycarbonyl2-methylsulphonyloxy- 1-prop-1(Z)-enyl]-azetidin-2-one.
Example 10 3S-(1 R-methylsulphonyloxsyethyl)-4R-benzthiazolyldithio-1-( -(I -methoxycarbonyl-2- methylsulphonyloxy-1 -prop-1 -enyl)-azetidin-2-one When in the reaction described in Example 9 the starting material was exposed to an excess (2 molar equivalents) of methanesulphonylchloride and triethylamine, the title product was obtained as a foam in quantitative yield as a mixture of E (20%) and Z (80%) isomers; #max (film 1780, 1730, 1360 and 1170 cm-1;; #(CDCl3) 1.58 (3H, d, J=6Hz, CH3.CH), 2.22 and 2.56 (3H, each s, =C.CH3 of E and Z isomers), 3.00 (3H, s, CH3SO2 on the hydroxyethyl chain), 3.20 (1 H, dd, J=2.2 and 4.5Hz, CH.CH.CH), 3.28 (3H, s, CH3SO2 on the crotonic appendage), 3.76 (3H, s, OCH3), 5.11(1 H, m, CH3.CH.CH) 5.52 (1 H, d, J=2.2Hz, CH.CH.S) and 7.30-7.95 ppm (4H, m, Ar).
By following the same procedure, but using THF as a solvent, 3S-(1R-methylsulphonyloxyethyl)- 4R-benzthiazolyldfthio- 1-[1 -diphenylmethoxycarbonyl-2-methylsulphonyloxy- 1-prop- 1 -(Z)-enyl]- azetidin-2-one was prepared and displayed the following spectral data: PmaX (film) 1777, 1728, 1360 and 1170 cm-1; #(CDCl3) 1.50 (3H, d, J=6Hz, CH3.CH), 2.52 (3H, s, =C.CH3), 2.9 (3H, s, CH3SO2 on the hydroxyethyl chain), 3.23 (3H, s, CH3SO2 on the crotonic appendage), 3.62 (1 H, dd, J=2.5 and 5.5Hz, CH.CH.CH), 5.05 (1H, m, CH3.CH.CH), 5.45 H, d, J=2.5Hz, CH.CH.S), 6.95 ( 1 H, s, OCHPh2) and 7.10-7.95 ppm (14H, m, Ar).
Example 11 3S-( 1 R-t-butyidimethyis;iyloxyethyl)-4R-benzthiazolyidithio-1 -methoxycarbonyl-2-trifluoromethylsulphonyloxy-1 -prop-1-enyl )-azetidin-2-one 300 mg of crude 3S-( 1 R-t-butyldimethylsilyloxyethyl)-4R-benzthiazolyldithio-1-(1-methoxy- carbonyl-2-hydroxy-1-prop-1-enyl)-azetidin-2-one in 5 ml of THF at 400 C was sequentially treated with 0.170 ml of triethylamine and 0.180 ml of trifluoromethanesulphonic anhydride.Work-up and chromatography gave the two separate geometric isomers of the title product, as foams: E isomer: Vmax (CHCl3) 1778, 1730, 1420, 1215 and 1135 cm-1(CDCl3) 0.08 (6H, s, SiMe2), 0.86 (9H, s, SiBut), 1.26 (3H, d, J=6Hz, CH3.CH), 2.05 (3H, s, =C.CH3), 3.46 (1 H, dd, 2.2 and 4Hz, CH.CH.CH), 3.81 (3H, s, OCH3),4.28(1H,m, CH3.CH.CH), 5.76 (1 H, d, J=2.2Hz, CH.CH.S) and 7.25-7.90 (4H, m, Ar); Z isomer (inter alia) #(CDCl3) 2.45 (3H, s =C.CH3), 3.40 (1 H, dd, J=2 and 4Hz, CH.CH.CH), 3.64 (3H, s, OCH2), 4.30 (1H, m, CH3.CH.CH) and 5.65 ppm (1H, d, J=2Hz, CH.CH.S).
Example 12 Methyl (7S,6R)-7-( I R-t-butyldimethylsilyloxyethyl)-3-methyl-2-thiacephem-4-carboxylate A solution of 0.5 ml of triethylamine in 10 ml of dichloromethane was saturated at -50 C with hydrogen sulphide. After purging with nitrogen, 0.34 ml of this solution was added to a cold (-50 C) solution of 75 mg (0.121 mmol) of 3S-(1 R-t-butyldimethylsilyloxyethyl)-4R-benzthiazolyldithio 1 - (1-methoxycarbonyl-2-methylsulphonyloxy-1 -prop-1-enyl)-azetidin-2-one. The mixture was allowed to warm up to room temperature and then washed with water, dried on anhydrous sodium sulphate and evaporated.Separation of the new compound from the formed 2-mercaptobenzthiazole and minor impurities was achieved by silica gel chromatography (ethyi acetate; cyclohexane as eluant), thus obtained the title compound as white crystals (19 mg, 20%), mp 85-870C, #max (EtOH) 223 (E=4,773), 277 (6,335), and 326 (2,922) nm, Vrnax (CHCI3 film) 1785 and 1730 cm (CDCI3) 0.08 (6H, s, SiMe2), 0.88 (9H, s, SiBut), 1.25 (3H, d, J=6Hz, CH3.CH), 2.22 (3H, s, CH3), 3.07 (1 H, dd, J=2.2 and 3.5Hz,CH.CH.CH), 3.8 (3H, s, OMe), 4.36 H, H, m. CH3.CH.CH) and 4.62 ppm (1H, d, J=2.2Hz, CH.CH.S).
Found: C, 49.08; H, 6.96; N, 3.52; S, 1 5.16. C,6H27NO4SiS2 requires C, 49.32; H, 6.99; N, 3.60; S, 16.46%.
When, instead of hydrogen sulphide and triethylamine, a solution of NaHS (0.9 mol equiv) in DMF was used, and quenching (partition between water and ethyl acetate) followed within 1 minute at OOC, the isolated yield of the pure title product was raised to 40-45%.
When the above process was performed on the geometrical Z isomer of the starting material, the yield was further enhanced (up to 60-65%). On the contrary, the E isomer afforded only a very low amount of the title product.
By following the same experimental procedure, methyl (7R,6R)-7-(1R-t- butyldimethylsilyloxyethyl)-3-methyl-2-thiacephem-4-carboxylate was obtained starting from 3 R-( 1 Rt-butyldimethylsilyloxyethyl)-4R-benzthiazolyldithio-1-( 1 -methoxycarbonyl-2-methylsulphonyloxy- prop-l -enyl)-azetidin-2-one; #max (film) 1785 and 1725 cm-1; #(CD3COCD3) 0.03 and 0.05 (each 3H, s, SiMe2), 0.84 (9H, s, SiBut), 1.19 (3H, d, 6.5Hz, CH3.CH), 2.08 (3H, s, CH3), 3.72 (3H, s, OCH3), 4.11 ( 1 H, dd, J=5.5 and 8.0Hz, CH.CH.CH), 4.20 H, m, CH3.CH.CH) and 5.01 ppm (iH, d, J=5.5Hz, CH.CH.S).
Example 13 Methyl (7S,6R)-7-(1 R-hydroxyethyl)-3-methyl-2-thiacephem-4-carboxylate 145 mg (0.287 mmol) of crude 3S-(1 R-hydroxyethyl)-4R-benzothiazolyldithio-1 -(1 -methoxycarbonyl-2-methylsulphonyloxy-1-prop-1-enyl)-azetidin-2-one, prepared as described in Example 9, was dissolved in 2 ml of an hydros dimethylformamide and treated at +200C with a freshly prepared solution of 1 6 mg (0.287 mmol) of NaHS in 1.6 ml of the same solvent. The mixture was stirred for 2 minutes and then partitioned between ethyl acetate and water.
After repeated washings with water, the solvent was removed leaving a residue which was purified by pressure chromatography on silica gel (ethyl acetate:cyclohexane as eluant) to give the pure title product in 45% yield as a white powder; #max (nujol) 3400, 1770 and 1720 cm-1; #(CDCl3) 1.37 (3H, d, J=7Hz, CH3.CH); 2.22 (3H, s, CH3), 2.40 (1 H, br s, OH), 3.12 (1 H, dd, J=2.0 and 4.5Hz, CH.CH.CH), 3.86 (3H, s, OCH3), 4.35 (lH, m, CH3.CH.CH) and 4.65 ppm (1H, d, J=2.0Hz, CH.CK.S).
By following a similar experimental procedure, there were obtained: Diphenylmethyl (7S,6R)-7-(1R-hydroxyethyl)-3-methyl-2-thiacephem-4-carboxylate, starting from 3 S-( 1 R-hydroxyethyl )-4R-benzthiazolyldithio-1-(1 -di phenyl methoxyca rbonyl-2-methylsulphonyloxy-1-prop-1-enyl)-azetidin-2-one; #max (EtOH) 281 (#=5,900) and 326 (3,670) nm; #max (KBr) 3550-3250, 3080, 3060, 3020, 2960, 2920, 2840, 1775, 1720, 1660 and 1490 cm-'; #(CDCl3) 1.36 (3H, d, J=6.5Hz, CH3.CH), 2.17 (3H, s, CH3), 3.12 (1 H, dd, J=2.0 and 5Hz, CH.CH.CH), 4.36(1H,m, CH3.CH.CH), 4.76 (1H, d, J=2.0Hz, CH.CH.S), 6.97 (1H, s, OCH2Ph) and 7.30 ( 10H, m, Ar);; Diphenylmethyl (7S,6S)- 7-r1 R-t-butyidimethylsilyloxyethyl)-3-methyl-2-thiacephem-4- carboxylate, starting from 3S-( 1 R-t-butyldimethylsilyloxyethyl)-4R-benzthiazolyldithio-1-(1-diphenyl- methoxycarbonyl-2-methylsulphonyloxy-1-prop-1-enyl)-azetidin-2-one;S(CDCI3) 0.06 (6H, s, SiMe2); 0.83 (9H, s, SiBut); 1.27 (3H, d, J=6.5Hz, CK3.CH), 2.05 (3H, s, CH3), 3.08 ( 1 H, dd, J=3.0 and 5.0Hz, CH.CH.CH), 4.32 (1 H, m, CH3.CH.CH), 4.60 (1 H, d, J=3.0Hz, CH.CH.S), 7.02 (1 H, s, OCHPh2) and 7.30 ppm (10H,s,Ar); t-Butyl (75, 6R)-7-(1R-t-butyldimethylsilyloxyethyl)-3-methyl-2-thiacephem-4-carboxylate, starting from 3 S-( 1 R-t-butyldimethylsilyloxyethyl)-4R-benzthiazolyldithio-1-(1 -t-butoxycarbonyl-2methylsulphonyloxy-1-prop-1-enyl)-azetidin-2-one; #max (CHCl3) 278 (e=6,300) and 327 nm (E=2,560); #max (CHCl3 film) 1780 and 1720 cm-';; #(CDCl3) 0.12 (6H, s, SiMe2), 0.88 (9H, s, SiBut), 1.25 (3H, d, J=6Hz, CH3.CH), 1.52 (9H, s, OBut), 2.10 (3H, s, CH3), 3.02 (1 H, dd, J=2.5 and 5Hz, CH.CH.CH), 4.28 (1 H, m, CH3.CH.C H) and 4.53 ppm (1 H, d, J=2.5Hz, CH.CH.S); Methyl (7S,6R)-7-(1 R-methylsulphonyloxyethyl)-3-methyl-2-thiacephem-4-carboxylate, starting from 3 S-( 1 R-methylsu Iphonyloxyethyl)-4R-benzthiazolyidithio-1-(1-methoxycarbonyl-2-methylsulphonyloxy-1 -prop-1 -enyl)-azetidin-2-one; PmaX 1 780, 1725, 1360 and 1175 cm-1; #(CDCl3) 1.60 (3H, d, J=6.5Hz, CH3.CH), 2.25 (3H, s, CH3), 3.07 (3H, s, CH3SO2), 3.27 (1 H, dd, J=2.2 and 5Hz, CH.CH.CH), 3.83 (3H, s, OCH3), 4.70 (1H, d, J=2.2Hz, CH.CH.S) and 5.24 ppm (1H, m, CH3CH.CH); Diphen ylmethyl (75, 6R)- 7-(1R-methylsulphonyloxyethyl)-3-methyl-2-thiacephem-4-carboxylate, starting from 3S-( 1 R-methylsulphonyloxyethyl)-4R-benzthiazolyldithio- 1 -(1 -diphenylmethoxycarbonyl2-methylsulphonyloxy-1-prop-1-enyl)-azetidin-2-one; Amax (CHCl3) 282 (E=7,080) and 330 (3,966) nm; PmaX (CHCl3 film) 1778, 1720, 1255 and 1170 cm-1;; S(CDCI3) 1.53 (3H, d, J=6Hz, CH3.CH), 2.10 (3H, s, CH3), 2.71 (3H, s, CH3SO2), 3.22 (1 H, dd, J=2.5 and 5.5 Hz, CH.CH.CH), 4.67 (1 H, d, J=2.5Hz, CH.CH.S),5.05 (1H, m, CH3.CH.CH); 6.90 (1 H, s, OCHPh2) and 7.25 (10H, s, Ar); Methyl (75, 6R)- 7-( 1 R-trichloroethoxycarbonyloxyethyl)-3-methyl-2-thiacephem-4-carboxylate, starting from 3 S-(1 R-trichloroethoxycarbonyloxyethyl)-4R-benzthiazolyidithio- 1 -(1 -methoxycarbonyl2-methylsulphonyloxy-1 -prop-1 -enyl)-azetidin-2-one; #max (film) 1 787, 1 760 sh, 1725 and 1250 cm-1;; #(CDCl3) 1.54 (3H, d, J=5.5Hz, CH3.CH),2.23 (3H, s, CH3), 3.30 (1 H, dd, J=2 and 7.5Hz, CH.CH.CH), 3.84 (3H, s, OCH3), 4.68 (iH, d, J=2Hz, CH.CH.S), 4.78 (2H, s, OCH2) and 5.37 ppm (1H, m, CH3.CH.CH); and Diphen ylmeth yl (75,6R)- 7-( 1 R-p-nitrobenzyloxycarbonyloxyethyl)-3-methyl-2-thiacephem-4- carboxylate, starting from (3S)-( 1 R-p-nitrobenzyloxycarbonyloxyethyl)-4R-benzthiazolyldithio-1 -(1 diphenylmethoxycarbonyl-2-methylsulphonyloxy-1-prop-1-enyl)-azetidin-2-one; #maX 1 787, 1745, 1720 sh cm-1; #(CDCl3) 1.53 (3H, d, CH3CH), 2.17 (3H, s, CH3), 3.28 (1 H, dd, J=2 and 6.5Hz, CH CH-CH), 4.65 (1 H, d, J=2Hz, CH.CH.S), 5.1 5 (2H, s, OCH2), 5.28 (1H, m, CH2.CH.CH),6.97(1H,s, OCHPh2), 7.2-7.5 (1 2H, m, Ar) and 8.17 ppm (2H, d, J=9Hz, Ar); and, likewise, there were obtained: t-butyl (75,6R)- 7-( 1R-trichloroethoxycarbonyloxyethyl)-3-methyl-2-thiacephem-4-carboxylate; diphenylmethyl (75, 6R)- 7-( 1 R-trichloroethoxycarbonyloxyethyl)-3-methyl-2-thiacephem-4- carboxylate; trichloroethyl (7S,6R)- 7-{ 1 R-trichloroethoxycarbonyloxyethyl)-3-methyl-2-thiacephem-4- carboxylate; trichloroethyl (75, 6R)- 7-( 1 R-t-butyld!methylsllyloxyethyl)-3-methyl-2-thiacephem-4-carboxylate; acetoxymethyl (75,6R)- 7-( 1 R-trichloroethoxycarbonyloxyethyl)-3-methyl-2-thiacephem-4carboxylate; acetoxymethyl (7S, 6R)- 7-( 1 R-t-butyldimethylsllyloxyethyl)-3-methyl-2-th!acephem-4- carboxylate; and a cetoxymethyl (7S, 6R)- 7-( 1 R-trimethylsllyloxyethyl)-3-methyl-2-thiacephem-carboxylate.
Example 14 3S-(1R-t-butyldimethylsilyloxyethyl)-4R-succinimidothio-1-(1-methoxycarbonyl-2-methyl-I prop-2-enyl)-azetidin-2-one A solution of 2.32 g of methyl 6a-(1 R-t-butyldimethylsilyloxyethyl)-penicillanate-1-oxide in 35 ml of dimethylacetamide was treated with 0.1 5 ml of acetic acid, purged with nitrogen, and heated for 3 hours at 1 050C in the presence of 5 g of N-trimethylsilylsuccinimide. After cooling to room temperature, the reaction mixture was partitioned between ethyl acetate and cold water.Fractionation of the material obtained from the organic layer (silica gel chromatography, ethyl acetate:cyclohexane) afforded the title product as a white foam, 1.2 g (43%); Vmax (CHCI3 film) 1770, 1735, 1710 sh and 1680 cm (CDCI3) 0.08 (6H, s, SiMe2), 0.87 (9H, s, SiBut), 1.32 (3H, d, J=6.5Hz, CH3.CH), 1.84 (3H, s,=C.CH3), 2.85 (4H, s, CO.CH2.CH2.CO), 3.29 (1H, dd, J=3 and 4.5Hz, CH.CH.CH), 3.73 (3H, sOMe), 4.24 (1 H, m, CH3.CH.CH), 4.66 (1 H, s, N.CH.CO), 4.85 (1 H, d, J=2.5Hz, CH.CH.S) and 5.00 ppm (2H, br s, CH2=C).
By following a similar experimental procedure, there were also obtained: 3S-(1R-t-butyldimethylsilyloxyethyl)-4R-succinimidothio-1-(1-diphenylmethoxycarbonyl-2methyl-1-prop-2-enyl)-azetidin-2-one, and 35-( 1 R-t-butyldime thylsllyloxye thyl)-4R-phthalimio(othio- 1-(1 -diphenylmethoxycarbonyl-2methyl-1-prop-2-enyl)-azetidin-2-one, both isolated as crude materials and used as such in the following steps.
Example 15 3S-( 1 R-t-butyldimethylsilyloxyethyl )-4R-phthalimidothio-I -[I -methoxycarbonyl-2methylsulphonyloxy-1 -prop-1 -(Z)-enyl]-azetidin-2-one A solution of 100 mg of 3S-( 1 R-t-butyldimethylsilyloxyethyl)-4R-benzothiazolyldithio- 1 -[1 - methoxycarbonyl-2-methylsulphonyloxy-1-prop-1-(Z)-enyl]-azetidin-2-one in 9 ml of acetone was treated with 34 mg of silver nitrate, soon followed by an ethanolic slurry of 30 mg of potassium phthalimide.After 30 minutes stirring at room temperature, the precipitate was collected partitioned between water and ethyl acetate, and purified by short silica gel chromatography to afford the title product (55%); Vmax (film) 1780, 1745 and 1725 cm-1; G(CDCI,) 0.1 (6H, s, SiMe2), 0.89 (9H, s, But), 1.4 (3H, d, CH3.CH), 2.2 (3H, s, =C.CH3), 3.05 (3H, s, SO2.CH3), 3.4 (1 H, m, CH.CH.CH), 3.6 (3H, s, OCH2), 4.2 (1 H, m. CH3.CH.CH), 5.45 (1 H, d, J=2Hz, CH.CH.S) and 7.8 ppm (4H, m, Ar).
Example 16 3S-( 1 R-t-butyldi methylsilyloxyethyl-4R-succinimidothio-1-(1-methoxycarbonyl-2-hydroxy-1prop-1 -enyl)-azetidin-2-one The title product was obtained by ozonolysis of 3S-( 1 R-t-butyldimethylsilyloxyethyl)-4Rsuccinimidothio-1-(1-methoxycarbonyl-2-methyl-1-prop-2-enyl)-azetidin-2-one in dichloromethane according to the procedure described in Example 8, and used as such for further reactions.A sample was characterized as its dimethylketal (MeOH/dry HCI): Vmax 1770, 1730 and 1715 sh cm (CDCI3) 0.04 and 0.09 (each 3H, s, SiMe2), 0.90 (9H, s, SiBut), 1.31 (3H, d, J=5Hz, CH3.CH), 1.49 (3H, s CH3), 2.84 (4H, s, COCH2.CH2CO), 3.21 and 3.26 (each 3H, s, ketal OCH3), 3.24 (1H, dd, J=2.5 and 5Hz), 3.73 (3H, s, ester OCH3), 4.20 ( 1 H, m, CH3.CH.CH), 4.43 ( 1 H, s, N.CH.CO) and 4.94 ppm ( 1 H, d, J=2.5Hz).
Likewise, 3S-(1R-t-butyldimethylsilyloxyethyl]-4R-phthalimidothio-1-(1- diphenylmethoxycarbonyl-2-hydroxy- i-prop- 1 -enyl)-azetidin-2-one was obtained starting from 3S (1 R-t-butyldimethylsilyloxyethyl)-4R-phthalimidothio-1-(1-diphenylmethoxycarbonyl-2-methyl-1prop-2-enyl)-azetidin-2-one.
Example 17 Methyl (7S,6R)-7-(1 R-t-butyldimethylsilyloxyethyl)-3-methyl-2-thiacephem-4-carboxylate A solution of 400 mg of 3S-(1 R-t-butyldimethylsilyloxyethyl)-4R-phthalimidothio-1-(1- methoxycarbonyl-2-methylsulphonyloxy-1-prop-1-(Z)-enyl]-azetidin-2-one in 4 ml of dimethyl formamide was treated with 50 g of finely ground NaHS under vigorous stirring. As soon as the last reagent was dissolved, the reaction was quenched by partition between diethyl ether and water. Workup gave the title compound, identical with the sample described in Example 12.
Example 18 Methyl (7S,6R)-7-(1 R-t-butyldimethylsilyloxyethyl)-3-methyl-2-thiacephem-4-carboxylate 0.8 g of 3 S-( 1 R-t-butyldimethylsilyloxyethyl)-4R-succinimidothio-1-(1-methoxycarbonyl-1-prop- 2-enyl)-azetidin-2-one in dichloromethane was ozonized at -700C until tic showed complete conversion. Excess ozone was purged with nitrogen and 1 ml of dimethylsulphide was added. After 1 hour at room temperature, any volatile material was removed in vacuo and the residue reacted in dichloromethane at -200C to 0 C with equimolar amounts of triethylamine and mesyl chloride until conversion of the enol into the mesylates was judged complete by talc. The mixture was concentrated in vacuo and partitioned between ethyl acetate and a cold, aqueous solution of sodium bicarbonate.The organic layer was evaporated to afford the crude mixture of E,Z mesylates which without purification was treated with NaHS in DMF according to the procedure described in Example 13. Purification of the resulting product by silica gel chromatography afforded the title compound, identical with the material obtained according to Example 12.
By a similar procedure, Diphen ylmethyl (7S,6R)-7-(1R-t-butyldimethylsilyloxyethyl)-3-methyl-2-thiacephem-4- carboxylate was obtained, starting from 3S-(1 R-t-butyidimethylsilyloxyethyl)-4R-phthaiimidothio-1-(1- diphenylmethoxycarbonyl-2-methyl-1-prop-2-enyl)-azetidin-2-one, and showed the same spectral properties as the material previously described (Example 13).
Example 19 Methyl (7S,6R)-7-( I R-t-butyldimethylsilyloxyethyl)-3-[(1 -methyl-5-tetrazolylthio)-methyl]-2thiacephem4-carboxylate 120 mg of 3S-( 1 R-t-butyldimethylsilyloxyethyl)-4R-( 1 -methyl-5-tetrazolyldithio)-1 -(i -methoxy- carbonyl-2-[(1-methyl-5-tetrazolylthio)-methyl]-1-prop-2-enyl}-azetidin-2-one in dichloromethane was subjected to the reaction sequence reported in Examples 8,9 and 17 (ozonolysis, mesylation, reaction with NaHS).The crude product was partitioned between ethyl acetate and aqueous sodium bicarbonate solution, thus removing the liberated mercaptotetrazole; the organic layer was washed several times with water, evaporated and the residue fractionated by silica gel chromatography to afford the title product, 17 mg (17%; Vmax (film) 1787, 1725, 1587, 1360 and 1250 cm-';; S(CDCI3) 0.10 (6H, s, SiMe2), 0.89 (9H, s, SiBut), 1.26 (3H, d, J=6Hz, CK3-CH), 3.15 (1 H, dd, J=2.2 and 3.5Hz CH.CH.CH), 3.88 (3H, s, OMe), 3.92 (3H, s, NMe), 4.38 (1 H, m, CH3.CH.CH), 4.46 (2H, ABq, J=1 4Hz, separation of inner lines 14Hz) and 4.68 ppm (1 H, d, J=2.2Hz, CH.CH.S).
Example 20 3S-(1 R-t-butyldimethylsilyloxyethyl)-4R-phenylsulphonylthio-1-(1-methoxycarbonyl-2-methyl-1 prop-2-enyl)-azetidin-2-one 2.6 g of 3S-(1 R-t-butyldimethylsilyloxyethyl)-4R-benzthiazolyldithio- 1 -(1 -methoxycarbonyl-2methyl-1-prop-2-enyl)-azetidin-2-one, prepared as described in Example 7, in 160 ml of acetone and 1 8 ml of water was treated under vigorous stirring with 0.98 g of silver nitrate, immediately followed by 0.79 g of sodium benzenesulphinate in 60 ml of water. After 1 hour at room temperature the white precipitate was filtered off, and the filtrate concentrated in vacuo and then partitioned between water and ethyl acetate.Removal of the solvent from the organic layer left the title product as a yellowish powder (2.43 g, 98%), recrystallizable from cyclohexane (white leaflets, mp 105-106 C); ir (KBr) 3080, 3020,2960,2930,2900, 2860, 1770, 1750, 1330 and 1145 cm-1; #(CDCl3) 0.05 (6H, s, SiMe2), 0.98 (12H, s+d, SiBut and CH3.CH), 1.84 (3H, s, =C.CH3), 3.22 (1 H, dd, J=2 and 2.5Hz, CH.CH.CH), 3.75 (3H, s, OMe), 4.19 (1 H, m, CH3.CH.CH), 4.58 (1 H, s, N.CH.CO), 5.00 (2H, m, C=CH2), 5.37 (1 H, d, J=2Hz, CH.CH.S),7.60 and 7.96 ppm (3 and 2H, each m, Ar).
Found: C, 53.69; H, 6.99; N, 2.70; S,12.42%, C23H35NO6SiS2 requires C, 53.77, H, 6.87; N,2.74: S 12.48%.
By following the same procedure, there were also obtained: 3S-( 1 R-t-butyldim e thylsilyloxyeth yl)-4R-phen ylsulphon ylthio- 1 -(1 -t-butoxycarbonyl-2 -methyl- 1prop-2-en yl)-azetidin-2-one; 35-( 1 R-t-butyldimethylsllyloxyethyl)-4R-phenylsulphonylthio- 1-(1-diphenylmethoxycarbonyl-2- methyl -prop-2-enyl)-azetidin-2-one; 3S-( 1R-trichloroethoxycarbonyloxymethyl)-4R-phenylsulphonylthio- 1 -(i -methoxycarbonyl-2- methyl-1 -prop-2-en yl)-aze tidin-2-one; 3S-(1R-trichloroethoxycarbonyloxyethyl)-4R-phenylsulphonylthio-1-(1 -trichloroethoxycarbonyl- 2-methyl- -prop-2-en yl)-azetidin-2-one.
Example 21 3S-(1 R-t-butyldimethylsilyloxyethyl)-4R-phenylsulphonylthio-1 -[1 -methoxycarbonyl-2- methylsulphonyloxy-1 -prop-1 -(Z)-enyl]-azetidin-2-one Procedure A 1 g of 3S -(1 R-t-butyldimethylsilyloxyethyl)-4R-phenylsulphonylthio-1-(1-methoxycarbonyl-2- methyl-1-prop-2-enyl)-azetidin-2-one, prepared as described in Example 20, in dry dichloromethane was ozonized at -70 C. After purging with nitrogen, 3.5 ml of dimethylsulphide was added and the mixture was stirred for 3 hours at room temperature. After removal of any volatile material in vacuo, the residue was partitioned between ethyl acetate and water.Evaporation of the solvent left the intermediate 3S-( 1 R-t-butyldimethylsilyloxyethyl)-4R-phenylsulphonylthio-1 -(1 -methoxycarbonyl-2hydroxy-1-prop-1-enyl)-azetidin-2-one; PmaX 3450, 1778, 1658 and 1620 cm-1; 6 (CDCl3) 0.08 (6H, s, SiMe2), 0.90 (9H s, SiBut), 1.13 (3H, d, J=6Hz, CH3.CH), 1.90 (3H, s, =C.CH3), 3.12 (1 H, dd, J=2.5 and 4Hz, CH.CH.CH), 3.72 (3H, s, OMe), 4.2 ( 1 H, m, CH3.CH.CH), 5.52 ( 1 H, d, J=2.5Hz, CH.CH.S), 7.4-8.0 (5H, m, Ar) and 13 ppm (1 H, s, OH).
This material was mesylated with 0.272 ml of triethylamine and 0.151 ml of mesyl chloride in 10 ml of dry THF according to the procedure of Example 10, thus obtaining the title product as a foam, 550 mg after silica gel chromatography; ir (film) 1 780, 1 730, 1640, 1370 and 1145 cm-1; 8(CDCI3) 0.05 (6H, s, SiMe2), 0.80 (9H, s, SiBut), 0.97 (3H, d, J=6Hz, CH3.CH), 2.50 (3H,s, =C.CH3), 3.1 5 (4H m, SO2CH3 and CH.CH.CH), 3.76 (3H, s, OCH3), 4.13 ( 1 H, m, CH3.CH.CH), 5.7 ( 1 H, d, J=2.8Hz, CH.CH.S) and 7.6-8.0 ppm (5H, m, Ar).
Procedure B 100 mg of 3S-( 1 R-t-butyldimethylsilyloxyethyl)-4R-benzthiazolyldithio-1 -[1 -methoxycarbonyl-2methylsulphonyloxy-1 -prop-1 (Z)-enyl]-azetidin-2-one in 9 ml of acetone and 1 ml of water was sequentially treated under stirring with 34.3 mg of silver nitrate and 26.6 mg of sodium benzenesulphinate in 4 mi of water. After 1 5 minutes at room temperature the precipitated silver benzthiazolemercaptide was removed by filtration and the solution partitioned between dichloromethane and water. Removal of the solvent left the title product as a syrup (quantitive yield), having the same spectral properties as the sample from procedure A.
According to the same methodology, there were obtained: 3S-(1 R-t-butyldimethylsllyloxyethyl)-4R-phenylsulphonylthio- 1 -[1 -t-butoxycarbonyl-2methylsulphonyloxy- 1-prop-1 (Z)-enyl]-azetidin-2-one; and 3S-(1R-trichloroethoxycarbonyloxyethyl)-4R-phenylsulphonylthio- 1 -[1 -trichloroethoxycarbonyl2-methylsulphonyloxy- 1 -prop-1(Z)-enyl]-azetidin-2-one.
Example 22 Methyl (7S,6R)-7-(1 R-t-butyldimethylsilyloxyethyl)-3-methyl-2-thiacephem-4-carboxylate 3S-( 1 R-t-butyldimethylsilyloxyethyl)-4R-phenylsulphonylthio-1-( 1 -methoxycarbonyl-2- methylsulphonyloxy-1 -prop-1 Z-enyl)-azetidin-2-one was allowed to react with NaHS in DMF following the procedure described in Example 13 thereby obtaining the title product, identical with the material previously described. This preparation allows for a simpler purification of the product, since the byproduct, sodium benzenesulphinate, is soluble in water and does not need chromatographic separation orfractional crystallization to be removed (unlike, e.g. mercaptobenzthiazole).
According to the same methodologies, there were obtained: t-Butyl (7S, 6R)- 7-( 1 R-t-butyldimethylsilyloxyethyl)-3-methyl-2-thiacephem-4-carboxylate; and Trichloroethyl (7S, 6RJ- 7-( 1 R-trichloroethoxycarbonyloxyethyl)-3-methyl-2-thiacephem-4 carboxyla te.
Example 23 3S-( 1 R-trichloroethoxycarbonyloxyethyl)-4R-acetyldithio-1 -(1 -methoxycarbonyl-2- methylsulphonyloxy-1 -prop-1 Z-enyl)-azetidin-2-one A solution of 340 mg of 3S-( 1 R-trichloroethoxycarbonyloxyethyl)-4R-benzthiazolyldithio-1-(1- methoxycarbonyl-2-methylsulphonyloxy-1 -prop-1 Z-enyl)-azetidin-2-one in 5 ml of THF was treated with 0.043 ml of thioacetic acid.Five minutes later the mixture was evaporated and the crude reaction product freed from 2-mercaptobenzthiazole by chromatography to obtain the pure title compound as a colourless syrup, 280 mg (96%); Vmax (film) 1775, 1760 sh, 1 730 br cm (CDCI3) 1.50 (3H, d, CH3.CH), 2.48 (3H, s, =C.CH3), 2.62 (3H, s, COCH3), 3.29 (3H, s SO2CH3),3.44(1H,dd,CH.CK.CH), 3.83 (3H, s OMe), 4.77 (2H, ABq, J=11.5Hz, separation of inner lines 2Hz), 5.24 (1 H, d, CH.CH.S) and 5.25 (1 H, m, CH3.CH.CH).
Example 24 Methyl (7S,6R)-7-(1 R-trichloroethoxycarbonyloxyethyl)-3-methyl-2-thiacephem-4-carboxylate A solution of 140 mg of 3S-( 1 R-trichloroethoxyca rbonyloxyethyl)-4R-acetyldithio- 1 -(1 methoxycarbonyl-2-methylsulphonyloxy-1 -prop- 1 Z-enyl)-azetidin-2-one, prepared as described in Example 23, in 10 ml of THF was treated at 0 C with a solution of 65 mg of tetrabutylammonium hydrogen sulphide in the same solvent.
Work-up and chromatography afforded the title product: Amax (EtOH) 280 (E4,974) and 327 nm (2,262); #max (film) 1787, 1769 sh, 1725 cm~1; S(CDCI3) 1.54 (3H, d, CH3.CH), 2.23 (3H, s, CH3), 3.30 (1 H, dd, 2 and 7.5Hz, CH.CH.CH), 3.84 (3H, s, OMe), 4.68 (1 H, d, CH.CH.S), 4.78 (2H, s, OCH2CCl3) and 5.3Hppm(1H, m, CH3.CH.CH), followed by some recovered starting material.
Example 25 Methyl (7S,6R)-7-(1R-t-butyldimethylsilyloxyethyl)-3-bromomethyl-2-thiacephem-4-carboxylate 0.52 g of methyl (7S,6R)-7-(1 R-t-butyldimethylsilyloxyethyl)-3-methyl-2-thiacephem-4carboxylate, 0.95 ml of propylene oxide, 0.52 g of N-bromosuccinimide and 0.05 g of azobisisobutyronitrile in 40 ml of carbon tetrachloride were refluxed for six hours. The reaction mixture was cooled to room temperature and filtered.The filtrate was evaporated in vacuo and the residue was purified by silica gel column eluting with ethyl acetate: hexane mixtures, thus obtaining the title product as a yellowish oil (80%); Amax (CHCl3) 282 and 336 nm; Vmax (CHCI3 film) 1785, 1730 cm-1; #(CDCl3) 0.10 (6H, s, SiMe2), 0.89 (9H, s, SiBut), 1.28 (3H, d, CH3.CH.OSi), 3.23 ( 1 H, dd, J=2.0 and 3.5Hz, CH.CH.CH), 3.87 (3H, s, OCH3), 4.65 (2H, center ABq, s.i.l. 4Hz, J=1 1.5Hz, CH2Br), 4.30 ( 1 H, m, CH3.CH.CH) and 4.76 ppm ( 1 H, d, J=2.0Hz, CH.CH.S).
Found: C, 41.1; H, 5.64; N, 3.01; S, 13.55; Br, 17.20; C,6H26BrNO4SiS2 requires C, 41.02; H, 5.59; N, 2.99; S, 13.69; Br, 17.06.
By following a similar procedure, there were obtained: t-butyl (7S,6R)-7-F 1 R-t-butyldimethylsilyloxyethyl)-3-bromomethyl-2-thiacephem-4-carboxylate; #max (CDCl2) 283 and 332 nm; #max (film) 1787 and 1720 cm-1; #(CDCl3) 0.9 (6H, s, SiMe2), 0.9 (9H, SiBut), 1.28 (3H, d, CH3.CH), 1.55 (9H, s, Obut), 3.18 (1 H, dd, J=2.5 and 4.5Hz, CH.CH.CH), 4.35 (3H, m, CH2Br) and CH3.CH.CH) and 4.71 ppm (1H, d, J=2.5Hz, CH.CH.S); p-nitrobenzyl (7S,6R)-7-(1 R-p-nitrobenzyloxycarbonyloxyethyl)-3-bromomethyl-2-thiacephem-4- carboxylate; #(CDCl3) 1.45 (3H, d, CH3.CH), 3.43 (1 H, dd, J=2.5 and 6Hz, CH.CH.CH), 4.45 (2H, ABq, J=1 2Hz, CH2Br), 4.80 (1 H, d, J=2.5Hz, CH.CH.S), 5.2, 5.5 (5H, m, two OCH2Ar) and CH3.CH.CH); 7.47 and 7.60 (each 2H, d, J=8.5Hz, Ar), and 8.20 ppm (4H, d, J=8.5Hz, Ar); diphenylmethyl (7S, 6R)- 7-(1R-p-nitrobenzyloxycarbonyloxyethyl)-3-bromoethyl-2-thiacephem- 4-carboxylate; #(CDCl3) 1.45 (3H, d, CH3.CH), 3.32 (1 H, dd, J=3 and 6Hz, CH.CH.CH), 4.18 (2H, ABq, J=1 1 Hz, CH2Br), 4.70 ( 1 H, d, J=3Hz, CH.CH.S), 5.20 (2H, s, OCH2Ar), 5.30 ( 1 H, m, CH3.CH.CH), 6.97 ( 1 H, s, OCHPh2), 7.10-7.40 (10H, br s, Ar), 7.45 and 8.15 ppm (each 2H, d,J=9Hz,Ar); diphenyl (7S,6R)-7-(1 R-t-butyldimethylsilyloxyethyl)-3-bromomethyl-2-thiacephem-4-carboxylate; Vmax (film) 1790 and 1730 cm-1;; d(CDCI3) 0.05 (6H, s, SiMe2), 0.8 (9H, s, SiBut), 1.22 (3H, d, J=6.5Hz, CH3.CH), 3.10(1 H, dd, J=2.7 and 4.5Hz, CH.CH.CH), 4.05 (2H, s, CH2Br), 4.2 (1H, m, CH3.CH.CH), 4.63 ( 1 H, d, J=2.7Hz, CH.CH.S), 6.92 ( 1 H, s, OCHPh2), and 7.05-7.40 ppm (1 OH, m, Ar); Amax (CHCl3) 283 (E=7,867) and 336 nm (E=3,533); trichloroethyl (75, 6R)- 7-( 1R-t-butyldimethylsilyloxyethyl)-3-bromomethyl-2-thiacephem-4- carboxylate; and trichloroethyl (7S, 6R)- 7-( 1 R-trichloroeth ox ycarb on ylox ye th yI)-3-bromome th yl-2-th!acephem-4- carboxylate.
Example 26 Methyl (7S,6R)-7-(1 R-t-butyldimethylsilyloxyethyl)-3-[(1 -methyl-5-tetrazolylthio)-methyl]-2- thiacephem-4-carboxylate A THF solution of crude methyl (7S,6R)-7-( 1 R-t-butyldimethylsilyloxyethyl)-3-bromomethyl-2thiacephem-4-carboxylate was kept overnight in the presence of sodium 1-methyl-tetrazole-5- mercaptide bihydrate (3 mol equiv). Work-up and chromatography afforded the title product as an oil in 85% yield; Amax (EtOH) 281 and 333 nm; ';max (film) 1790 and 1725 cm-1;#(CDCl3) 0.10 (6H, s, SiMe2), 0.89 (9H, s, But), 1.26 (3H, d, CH3.CH), 3.1 5 (1 H, dd, J=2.2 and 3.5Hz, CH.CH.CH), 3.88 (3H, s, OMe), 3.92 (3H, s, N.CH3), 4.38 (1 H, m, CH3.CH.CH), 4.46 (2H, Abq. sep. of inner lines 14Hz, J=1 4Hz) and 4.68 ppm (1 H, d, CH.CH.S, J=2.2Hz).
By following a similar procedure, there were obtained: t-butyl (75,6R)- 7-( 1 R-t-butyldimethylsilyloxyethyl)-3-[( 1 -methyl-5-tetrazolylthio)-methyll-2- thiacephem-4-carboxylate, starting from t-butyl (7S,6R)-7-(1 R-t-butyldimethylsilyloxyethyl-3bromomethyl-2-thiacephem-4-carboxylate; and diphenylmethyl(7S,6R)-7-(1R-t-butyldimethylsilyloxyethyl)-3-{(8-aminotetrazolo[1,5-b]pyridazin- 6-ylthio)-methyl 1-2-thiacephem-4-ca rboxylate Example 27 (5aR,6S)-6-( 1 R-t-butyidimethylsilyloxyethyl)-5a,6-dihydro-3H,7H-azeto[2, 1 -c]furo[3,4-e] 1 ,2,4- dithiazine-1,7-dione Procedure A A solution of 15 mg of methyl (7S,6R)-7-(1 R-t-butyldimethylsilyloxyethyl)-3-bromomethyl-2thiacephem-4-carboxylate in 2 ml of DMSO and 1.5 ml of water was stirred with 50 mg of cuprous oxide at 500C for 221 hours. The reaction mixture was partitioned between water and ethyl acetate.
Evaporation and chromatography of the organic extracts afforded the title product as a white powder; Vmax (CHCI3 film) 1800-1760 br cm-1; X(CDCI3) 0.06 (3H, s, SiCH3), 0.1 1 (3H, s, SiCH3), 0.90 (9H, s, But), 1.33 (3H, d, C.H3.CH), 3.33 1 H, dd, J=2.5 and 4.5Hz, CH.CH.CH), 4.44(1 H, m, CH3.CH.CH), 4.62 (1H, d, J=2.5Hz, CH.CH.S) and 4.98 ppm (2H, s, CH2O).
Procedure B 250 mg of the 2-bromomethyl precursor in 35 ml of acetone:water (2:1 by volume) was stirred for 15 minutes at 0 C with 153 mg of silver perchlorate. The reaction mixture was partitioned between water and ethyl acetate and the organic layer was evaporated off to leave a residue. Silica gel chromatography afforded the title product, identical with the sample described above under A).
Example 28 t-Butyl (7S,6R)-7-( 1 R-t-butyldimethylsilyloxyethyl)-3-hydroxymethyl-2-thiacephem-4carboxylate 300 mg of t-Butyl (7S,6 R)-7-( 1 R-t-butyldimethylsilyloxyethyl)-3-bromomethyl-2-thiacephem-4carboxylate in 10 ml of a 2:1 by volume acetone:water mixture was stirred for 15 minutes at 0 C with 1 50 mg of silver perchlorate.Removal of the solvent, followed by water:ethyl partition and work-up of the organic layer, gave 250 mg (96%) of the title product; Amax (CHCl3) 281 and 335 nm; Vmax (film) 3450, 1785 and 1712 cm (CDCI3) 0.1 (6H, s, SiMe2), 0.86 (9H, s, SiBut), 1.25 (3H, d, CH3CH), 1.50 (9H, s, OBut), 3.13 (1 H, dd, J=2.5 and 4.5Hz, CH.CH.CH), 4.25 (centre of ABq, J=1 3Hz, CH2OH), 4.37 ( 1 H, m, CH3.CH.CH) and 4.60 ppm ( 1 H, d, J=2.5Hz, CH.CH.S).
Example 29 t-Butyl (7S,6R)-7-(1R-t-butyldimethylsilyloxyethyl)-3-(N-trichloroacetylcarbamoyloxymethyl)-2- thiacephem-4-carboxylate 250 mg of t-Butyl (7S,6R)-7-( 1 R-t-butyldi methylsilyloxyethyl)-3-hydroxymethyl-2-thiacephem4-carboxylate in 2.5 ml of ethanol-free dichloromethane was treated at -400C with 0.080 ml of trichloroacetylisocyanate. The mixture was allowed to rise to room temperature and then sequentially washed with 2% aqueous sodium bicarbonate solution and brine.Evaporation of the solvent from the organic layer gave the title product in quantitative yield: Amax (EtOH) 275 and 329 nm; Vmax 1795 and 1725 br cm-1; d(CD3CN), 0.1 (6H, s, SiMe2), 0.9 (9H, s, SiBut), 1.3 (3H, d, CH3.CH), 1.5 (9H, s, OBut), 3.40 ( 1 H, dd, J=3 and 4Hz, CH.CH.CH), 4.35 ( 1 H, m, CH3.CH.CH), 4.80 ( 1 H, d, J=3Hz, CH.CH.S) and 5.0 ppm (centre of Abq, CH20CO).
Example 30 t-Butyl (7S,6R)-7-( 1 R-t-butyldimethylsilyloxyethyl)-3-carbamoyloxymethyl-2-thiacephem-4carboxylate A methanolic solution of t-butyl (7S,6R)-7-(1 R-t-butyldimethylsilyloxyethyl)-3-(N-trichloroacetylcarbamoyloxymethyl)-2-thiacephem-4-carboxylate, prepared as described in Example 29, was stirred with silica gel for 20 hours. The slurry was then charged onto a silica gel column and the product eluted with ethyl acetate; b(CDCI3) 0.1 (6H, s, SiMe2), 0.9 (9H, s, SiBut), 1.35 (3H, d, CH3.CH), 1.60 (9H, s, OBut), 3.1(1H, dd, CH.CH.CH), 4.3 (1 H, m, CH3.CH.CH) 4.75 (1 H, d, J=3Hz, CH.CH.S) and 5.0 ppm (centre of ABq, OCH2CO).
Example 31 Methyl (7S,6R)-7-( 1 R-t-butyldimethylsilyloxyethyl)-3-nitrooxymethyl-2-thiacephem-4carboxylate A solution of 200 mg of methyl (7S,6R)-7-( 1 R-t-butyldimethylsilyloxyethyl)-3-bromomethyl-2thiacephem-4-carboxylate in 20 ml of acetone was stirred for 20 minutes in the presence of 100 mg of silver nitrate.The filtered reaction mixture was fractionated by silica gel chromatography to obtain the title product, 120 mg; Amax (CHCl3) 280 and 337 nm; VmaX (film) 1790, 1730, 1640 and 1280 cm-1 8(CDCI3) 0.08 (6H, s, SiMe2), 0.87 (9H, s, SiBut), 1.38 (3H, d, CH3.CH), 3.18 (1 H, dd, J=2.5 and 5.5Hz, CH.CH.CH), 3.85 (3H, s, OMe), 4.38 ( 1 H, m, CH 3.CH.CH), 4.73 ( 1 H, d, J=2.5Hz, CH.CH.S) and 5.36 ppm (2H, ABq, J=1 3.5Hz, s.i.l. 29.5Hz, CH2ONO2); further elution then afforded some of the lactone described in Example 27.
Example 32 Methyl (7S,6R)-7-( 1 R-t-butyl di methylsilyloxyethyl)-3-formyloxymethyl-2-thiacephem-4- carboxylate 200 mg of methyl (7S,6R)-7-(1 R-t-butyldimethylsilyloxyethyl)-3-bromomethyl-2-thiacephem-4carboxylate in dichloromethane was treated at daily intervals with tetrabutylammonium formate (3x600 mg). After 3 days at 50C, tic showed 80% conversion in the product (ethyl acetate:light petroleum 1:2 by volume). Elution through a short silica gel column gave the title material; d(CDCI3) 0.1 (6H, s, SiMe2), 0.9 (9H, s, SiBut), 1.3 5 (3H, d, CH3.CH), 3.20 (iH, dd, 2.5 and 7Hz, CH.CH.CH), 3.9 (3H, s, OMe), 4.5 (1 H, m, CH3.CH.CH), 4.74 (1 H, d, 2.5Hz, CH.CH.S) and 5.13 ppm (centre of ABq, CH2O).
In a similar way, starting from the corresponding t-butyl and diphenylmethyl esters, there were obtained: t-butyl (7S,6R)- 7-( 1 R-t-butyldimethylsllyloxyethyl)-3-formyloxymethyl-2-thiacephem-4- carboxylate; and diphenylmethyl (75, 6R)- 7-(1R-t-butyldimethylsilyloxyethyl)-3-formyloxymethyl-2-thiacephem-4- carboxylate and, in a likewise fashion, the corresponding acetates were obtained.
methyl (7S, 6R)- 7-( 1 R-t-butyldimethylsilyloxyethyl)-3-acetoxymethyl-2-thiacephem-4- carboxylate; t-butyl (7S,6R)-7-(1R-t-butyldimethylsilyloxyethyl)-3-acetoxymethyl-2-thiacephem-4- carboxylate; diphenylmethyl (75, 6R,i- 7-(1R-t-butyldimethylsilyloxyethyl)-3-acetoxymethyl-2-thiacephem-4- carboxylate; and trichloroethyl (75,6R)- 7-( 1 R-trichloroethoxycarbonyloxyethyl)-3-acetoxymethyl-2-thiacephem-4 carboxyla te.
Example 33 Methyl (7S,6R)-7-(1 R-hydroxyethyl )-3-methyl-2-thiacephem-4-carboxylate 0.75 g of methyl (7S,6R)-7-(1 R-t-butyldimethylsilyloxyethyl)-3-methyl-2-thiacephem-4carboxylate was added to a solution of 2.03 g of tetrabutylammonium fluoride trihydrate in 1.23 ml of acetic acid and 10 ml of THF. Work-up after 20 hours gave the title compound (virtually quantitative yield), showing the spectral properties described for the sample obtained in Example 1 3.
By similar experimental procedures, there were obtained: Methyl (75, 6R)-7-( 1 R-hydroxyethyl)-3-bromomethyl-2-thiacephem-4-carboxylate, starting from methyl (7 S, 6R)-7-( 1 R-t-butyldimethylsilyloxyethyl)-3-bromomethyl-2-thiacephem-4-ca rboxylate; #max (film) 1775, 1730 cm-1; #(CDCl3) 1.35 (3H, d, CH3.CH), 3.38 (1 H, dd, CH.CH.CH), 3.60 ( 1 H, br s, OH), 3.97 (3H, s, OMe), 4.33 ( 1 H, m, CH3.CH.CH), 4.46 (2H, centre of ABq, J=1 1 Hz, sep. of inner lines 4Hz, CH2Br)) and 4.88 ppm (1 H, d, J=2.2Hz, CH.CH.S);; Methyl (75,6R)- 7-( 1 R-hydroxye thyl)-3-[( 1 -methyl-5-tetrazolylthio)-methyl]-2-thiacephem-4- carboxylate, starting from methyl (7S,6R)-7-(1R-t-butyldimethylsilyloxyethyl)-3-[(1-methyl-5- tetrazolylthio)-methyl]-2-thiacephem-4-carboxylate; Vmax (KBr) 1765 and 1707 cm-1; 8(CD3COCD3), 1.30 (3H, d, CH3.CH), 3.39 (1 H, dd, CH.CH.CH), 3.79 (3H, s, NCH3), 3.97 (3H, s, OCH3), 4.0 ( 1 H, m, CH3.CH.CH), 4.38 (2H, centre of ABq, J=1 6Hz, separation of inner lines 13Hz, CH2.S), 4.77 ( 1 H, d, J=2.2Hz, CH.CH.S) and 5.0 ppm (1 H, br s, OH); and, analogously, the corresponding t-butyl, diphenylmethyl and trichloroethyl esters were also prepared.
Example 34 (7S,6R)-7-(1 R-methylsulphonyloxyethyl)-3-methyl-2-thiacephem-4-carboxylic acid Diphenylmethyl (7S,6R)-7-( 1 R-methylsulphonyloxyethyl)-3-methyl-2-thiacephem-4-carboxylate was dissolved in cold trifluoroacetic acid (0 C, neat). After 15 minutes stirring at the same temperature, carbon tetrachloride was added and the solution thoroughly evaporated under vacuum without external heating.The residue was triturated in carbon tetrachloride and collected, thus obtaining the title product; Amax (CHCl3) 281 and 326 nm; Vmax (CHCI3) 3000-2300,2970,2930, 2850, 1775, 1710, 1530 and 1170 cm-l; #(CD3COCD3) 1.58 (3H, d, CH3.CH), 2.23 (3H, s, Me), 3.16 (3H, s, SO2Me), 3.66 (1 H, dd, J=2 and 6Hz, CH.CH.CH), 4.85 (1 H, d, J=2Hz, CH.CH.S) and 5.30 ppm (1 H, m, CH3.CH.CH).
The same material was obtained by trifluoroacetic acid hydrolysis of the corresponding t-butyl ester, but prolonging the reaction time to about 1 hour.
Similarly hydrolyses of the t-butyl or diphenylmethyl precursors gave the following products: (7S, 6R)- 7-( 1 R-t-butyldimethylsilyloxyethyl)-3-methyl-2-thiacephem-4-carboxylic acid; (75, 6R)- 7-(1 R-hydroxyethyl]3-methyl-2-thiacephem-4-carboxylic acid; (75, 6R)- 7-( 1 R-hydroxyethyl)-3-ace toxymethyl-2-thiacephem-4-carboxylic acid; (75, 6R)-7-( l R-hydroxye thyl)-3-carbamoyloxymethyl-2-thiacephem-4-carboxyllc acid; and (7S,6R)-7-( 1 R-hydroxyethyl)-3-[( 1 -methyl-5-tetrazolylthio)-methyll-2-thiacephem-4-carboxylic acid.
Example 35 (7S,6R)-7-(1R-t-butyldimethylsilyloxyethyl)-3-methyl-4-methoxycarbonyl-2-thiacephem-1,1- dioxide Procedure A A solution of 117 mg of (7S,6R)-7-(1 R-t-butyldimethylsilyloxyethyl)-3-methyl-4-methoxycarbonyl-2-thiacephem in 5 ml of chloroform was treated with 220 mg of m-chloroperbenzoic acid at 0 C under stirring. After 30 minutes the reaction mixture was partitioned between dichloromethane and a 2% by weight aqueous sodium bicarbonate solution. The organic layer was dried over anhydrous sodium sulphate and the solvent was evaporated off.The residue was purified by short-path chromatography to afford the title product (89 mg) as a syrup; #max (CH2CI2 film) 1 800, 1735 cm-1; S(CDCI3) 0.10 (6H, s, Me2Si), 0.90 (9H, s, ButSi), 1.27 (3H, d, CH3-CH), 2.18 (3H, s, CH3), 3.81-3.83 (1 H, dd, +3H, s, CH-CH-CH and OCH3), 4.35 (1 H, m, CH3-CH-CH) and 5.05 ppm (1 H, d, J=2.0 Hz, CH-CH-S); #max (hexane) 276 (E=5,084) and 297 (sh, E=3,745) nm.
Procedure B A solution of 500 mg of (7 S,6R)-7-( 1 R-t-butyldimethylsilyloxyethyl)-3-methyl-4-methoxy carbonyl-2-thiacehem in 25 ml of chloroform was treated with 276 mg of 80% m-chloroperbenzoic acid at -20 C. The temperature was allowed to rise to +200C within 30 minutes and 4% by weight aqueous sodium bicarbonate solution was then added. The organic layer was dried over anhydrous sodium sulphate, and the solvent was evaporated off.The residue was separated by silica gel chromatography to afford in the following order:- dioxide, syrup, 35 mg; NMR and IR data as above;-- the 2-oxide, syrup, 60 mg; Vrnax (CH2CI2 film) 1795, 1740 cm-1; S(CDCI3) 0.10 (6H, s, Me2Si); 0.90 (9H, s, ButSi, 1.24 (3H, d, CH3-CH), 2.35 (3H, s, CH3); 2.85-3.90 (1 H, dd, +3H, s, CH-CK- CH and OCH3), 4.35 (1 H, m, CH3-CH-CH) and 5.27 ppm (1 H, d, J=2.5Hz, CH-CH-S); #max (hexane) 276 (E=5,092) nm;-the oxide, white powder, mp 90-93 C, 330 mg; Vmax (CH2Cl2film) 1790, 1730 cm-1; #0.10 (6H, s, Me2Si), 0.90 (9H, s ButSi) 1.28 (3H, d, CH3-CH), 2.24 (3H, s, CH3), 3.60 (1 H, dd, J=2.0 and 4.0Hz, CH-CH-CH), 3.87 (3H, s, OCH3), 4.35 (1 H, m, CH3-CH-CH) and 4.67 ppm (1 H, d, J=2.0HZ CH-CH-S); may (hexane) 273 (E=4.862), 309 (sh, E=2,721) nm.
The solution of 300 mg of the 1-oxide in 30 ml of chloroform was stirred for 1 hour at room temperature in the presence of 160 mg of m-chloroperbenzoic acid. The reaction mixture was washed with aqueous sodium bicarbonate solution, concentrated and purified by flash chromatography (silica gel, cyclohexane:ethyi acetate as eluent) thus obtaining a further 280 mg of the title product.
Example 36 Methyl (6S,5R)-6-[1 (R)-tert-butyldimethylsilyloxyethyl]-2-methylpenem-3-carboxylate A chloroform solution of 300 mg of the 1,1-dioxide prepared in Example 35 was heated at 50 C for 5 hours. Removal of the solvent afforded the title compound, free of stereoisomers, in nearly quantitative yield (250 mg); #max (CHCl3) 1795 1715 cm-1; #(CDCl3) 0.08 (6H, s, Me2Si), 0.89 (9H, s, ButSi), 1.23 (3H, d, CK3-CH); 2.33 (3H, s, CH3), 3.61(1 H, dd, J=1 .8 and 5.0Hz, CH-CK-CH), 3.75 (3H s, OCH3), 4.21 H, m, CH3-CH-CH) and 5.50 ppm ( 1 H, d, J=1 .8Hz, CH-CH-S); Amax (EtOH) 257,314 nm.
The above reaction occurred even at room temperature; e.g. after 16 hours standing in chloroform, NMR analysis revealed a mixture 1:2 of the title product and the starting material.
Example 37 (7S,6R)-7-(1 R-hydroxyethyl)-3-methyl-4-methoxycarbonyl-2-thiacephem-I 1-dioxide A solution of 40 mg of (7S,6R)-7-(1 R-hydroxyethyl)-3-methyl-4-methoxycarbonyl-2-thiacephem in 1 ml of chloroform was stirred at 0 C for 1 5 minutes in the presence of 60 mg of mchloroperbenzoic acid. Partition between ethyl acetate and an aqueous solution of sodium bicarbonate and removal of the solvent left the title compound, which was further purified by silica gel chromatography; #(CDCl3)1.36 (3H,d, J=6.4Hz, CK3-CH), 2.21 (3H, s, CH3), 3.80-3.88 (4H, m, CH-CH-CH and OCH2), 4.40 (1 H, m, CH3-CH-CH) and 5.08 ppm (1 H, d, J=1 .6Hz, CH-CH-S).
Example 38 Methyl (6S,5R)-6-( 1 R-hydroxyethyl)-2-methylpenem-3-carboxylate When a solution of the 1,1-dioxide prepared in Example 37 in an inert solvent (e.g. chloroform or benzene) was allowed to stand for a few days, or briefly heated at 50-80 C, the title compound was formed, free of diastereoisomers, in virtually quantitative yield. #(CDCl3) 1.34 (3H, d, J=6.4Hz, CH2- CH),2.35 (3H, s, CH3), 3.68 (1 H, dd, J=6.6 and 1.5Hz, CH-CH-CH), 3.80 (3H, s, OCH2),4.40 (1 H, m, CH2-CH-CH) and 5.56 ppm (1H, d, J=1.5Hz, CH-CH-S).
Example 39 Methyl (6S,5R)-6-(1 R-t-butyldimethylsilyloxyethyl)-2-[(1-methyl-5-tetrazolylthio)-methyl]- penem-3-carboxylate A solution of methyl (7S,6R)-7-(1 R-t-butyldimethylsilyloxyethyl)-3-[( 1 -methyl-5-tetrazolylthio)- methyl]-2-thiacephem-4-carboxylate in chloroform was stirred at 0 C with m-chloroperbenzoic acid (2.5 molar equivalent) for 30 minutes, and then washed with aqueous sodium bicarbonate solution.
The dried organic layer was refluxed for a few hours (tic monitoring).
Evaporation of the solvent and silica gel chromatography afforded the title product: S(CDCI3) 0.07 (6H, s, SiMe2) 0.82 (9H, s, SiBut), 1.20 (3H, d, CH3-CH), 3.68 ( 1 H, dd, 1.8 and 4Hz, CH.CH.CH), 3.80 (3H, s, N-Me), 3.81 (3H, s, OMe), 4.22 ( 1 H, m, CH3-CH-CH), 4.69 (2H, centre of ABq, J=1 4Hz, separation of inner lines 11.5Hz, CH2S) and 5.54 ppm (1 H, d, J=1.8Hz, CH-CH-S).
Example 40 p-Nitrobenzyl (7S,6R)-7-( 1 R-p-nitrobenzyloxycarbonyloxyethyl)-3-methyl-2-thiacephem-4- carboxylate A solution of 200 mg of diphenylmethyl (7S,6R)-7-(1 R-p-nitrobenzyloxycarbonyloxyethyl)-3methyl-2-thiacephem-4-carboxylate in 25 ml of dichloromethane was treated for 30 min at 0 C with 0.4 ml of trifluoroacetic acid. Evaporation under vacuum in the cold left the crude 2-thiacephem-4carboxylic acid, which was dissolved in 10 ml of acetonitrile:dimethylformamide (2:1 by volume) and treated with 0.050 ml of triethylamine and 100 mg of p-nitrobenzylbromide. After 1 hour at 250C, the mixture was partitioned between ethyl acetate and aqueous sodium bicarbonate solution.The organic layer, dried over anhydrous magnesium sulphate, was concentrated and the residue passed through a short silica column (ethyl acetate: light petrol as eluants) to afford the pure title product, 150 mg (79%); a(CDCl3) 1.45 (3H, d, CH3.CH), 3.43 ( 1 H, dd, J=2.5 and 6Hz, CH-CH-CH), 4.45 (2H, ABq, J=1 2Hz, CH2Br), 4.80 ( 1 H, d, J=2.5Hz, CH-CH-S), 5.2-5.5 (5H, m), 7.47 and 7.60 (each 2H, d, Ar) and 8.20 ppm (4H, d, Ar).
Example 41 (7S,6R)-7-(1 R-t-butyidimethylsilyloxyethyl)-4-diphenylmethoxycarbonyl-3-(pyridinium-methyl)- 2-thiacephem bromide A solution of 310 mg of diphenylmethyl (7S,6R)-7-(1 R-t-butyldimethylsilyloxyethyl)-3 bromomethyl-2-thiacephem-4-carboxylate in 1 5 ml of dry acetone was treated with 0.4 ml of pyridine.
After 20 hours at room temperature the solvent was distilled off and the residue purified by silica gel chromatography. The product-containing fractions (eluted with dichloromethane:acetic acid: methanol 70:1 5:1 5 by volume) were collected and freed from the solvents to leave the title compound as a syrup; Vmax (CHCI3 film) 1790, 1715 cm-1; S(CDCI3) (inter alia) 1.32 (3H, d, J=6.5Hz), 3.33 ( 1 H, dd), 4.45 (1 H, m), 5.0 (1 H, d, J < 2Hz) and 7.11 ppm (1 H, s);; #max (CHCl3) 283 and 337 nm (#=4,060). In a likewise manner, and starting from p-nitrobenzyl (7S,6R)-7-(1 R-p-nitrobenzyloxycarbonyloxyethyl)-3bromomethyl-2-thiacephem-4-carboxylate, there was obtained: (75,6R)-7-( 1R-p-nitrobenzyloxycarbonyloxyethyl)-4-p-nitrobenzyloxycarbonyl-3-(pyridinium- methyl)-2-thiacephem bromide.
Example 42 (7S,6R)-7-( I R-t-butyldimethylsilyloxyethyl)-4-carboxy-3-(pyridinium-methyl)-2-thiacephem trifluoroacetate A solution of (7S,6R)-7-( 1 R-t-butyldimethylsilyloxyethyl)-4-diphenylmethoxycarbonyl-3 (pyridinium-methyl)-2-thiacephem bromide, prepared as described in Example 41, in 10 ml of dichloromethane was treated with 2 ml of trifluoroacetic acid at 0 C for 1 5 minutes. After evaporation in vacuo, the residue was taken up in a small amount of chloroform.Diethyl ether was added under stirring and then decanted off, to leave the crude title product; VmaX (CHCI3 film) 3420, 1785, 1715 and 1635 br cm-1; 8(CDCI3) (inter alia) 1.30 (3H, d, J=6.5Hz), 3.23 (1 H, dd), 4.38 (1 H, m) and 4.76 ppm (1 H, d); Amax (CHCl3) 262 and 334 nm.
Example 43 (7S,6R)-7-( 1 R-p-nitrobenzyloxycarbonyloxyethyl)-4-p-nitrobenzyloxycarbonyl-3-(3- carbamoylpyridinium-methyl)-2-thiacephem bromide A solution of 460 mg of p-nitrobenzyl (7S,6R)-7-(1 R-p-nitrobenzyloxycarbonyloxyethyl)-3bromomethyl-2-thiacephem-4-carboxylate in 5 ml of DMF was stirred overnight in the dark in the presence of 200 mg of nicotinamide. Most of the solvent was distilled off and the residue taken up in 1 50 ml of tetrahydrofuran. This solution was washed with a solution of sodium chloride in 0.1 N hydrochloric acid (2x50 ml) and with brine (2x50 ml), dried on anhydrous sodium sulphate and evaporated to dryness. The residue was charged to the top of a column packed with silanised silica gel (Merck, Art. 7719).Excess nicotinamide and impurities were eluted with ethyl acetate, and the product was then collected by eluting with ethyl acetate:acetic acid (9:1 by volume). Evaporation in vacuo left the title product; PmaX (CHCl3) 1800, 1725, 1695 cm-1; #(Deuteroacetone; 200 MHz) 1.67 (3H, d, J=6.4Hz, C!l3-CH), 4.14 (1 H, dd, J=2.5 and 4.7Hz, CH-CH-CH), 5.30 (1 H, d, J=2.5Hz, CH-CH- S), 5.4-5.7 (7H, m, 2xCH2OAr, CH2N+, and CH3-CH-CH),7.7-8.4 (8H, mAr), and 8.0, 8.7, 9.5 and 9.7 ppm (each 1 H, br s, pyridinium).Analogously, by using isonicotinamide instead of nicotinamide, there was obtained: (75, 6R)- 7-( 1R-p-nitrobenzyloxycarbonyloxyethyl)-4-p-nitrobenzyloxycarbonyl-3-(4-carbamoyl- p yridinium-methyl)-2-thiacephem bromide.
Example 44 (6S,5R)-6-(1 R-hydroxyethyl )-2-(pyridinium-methyl )-penem-3-carboxylate A solution of (7 S,6R)-7-( 1 R-p-nitrobenzyloxyca rbonyloxyethyl)-4-p-nitrobenzyloxycarbonyl-3 (pyridinium-methyl)-2-thiacephem acetate (prepared from the corresponding bromide by conventional treatment with silver acetate or an ion-exchange resin) in chloroform was treated with 2 mol equivalents of peracetic acid at 0 C.Workup and gentle heating, according to the general procedure described in Examples 37-39, gave (6S,5R)-6-(1 R-p-nitrobenzyloxycarbonyloxyethyl)-3-p-nitrobenzyloxycarbonyl-2-(pyridinium-methyl)-penem acetate: #max (KBr) 1 795, 1 740, 1705 cm-1; #(CDCl3+deuteroacetone) 1.4 (3H, d, J=6.5Hz, CK3-CH), 4.10 (1 H, dd, J=1 .7 and 8Hz, CH-CH- CH), 5.20 and 5.31 (each 2H, s, OCH2Ar), 5.2 (1 H, m, CH3-CH-CH), 5.77 (1 H, d, J=1.7Hz, OH- CH-S), 6.05 (2H, ABq, J=1 5Hz, CH2N), 7.4-8.3 (11 H, m, Ar) and 9.15 ppm (2H, d, J=6Hz, o-Pyr).
300 mg of this material in 40 ml of tetrahydrofuran:water (1 :1 by volume) was treated with 5 g of ammonium chloride under stirring to obtain a clear solution. After cooling to about 10 C,2.5 g of iron powder was added under vigorous stirring; the reaction could be monitored by TLC (water:methanol :sodium chloride 9:1:1 by volume) by following the development of the product as a faster running spot. After about one hour, 3 g of celite was added and the whole filtered through a glass septum, washing with demineralised water. Removal of the organic solvent, followed by washings with diethyl ether, left an aqueous solution of the title product and inorganic salts.The former was obtained in pure form after reverse-phase chromatography and freeze-drying; (D2O, 200 MHz) 1.27 (3H, d, J=6.5Hz, CH3CH), 3.98 (1 H, dd, J=1 .4 and 5.8 Hz, CH-CH-CH)44.24 (1 H, m.
OH3-CH-CH), 5.69 (1H, d, J=1.4Hz, CH-CH-S), 5.94 (2H, ABq, J=14.9Hz, CH2N), 8.10 (2H, t, J=6.6Hz, pyridinium m-H), 8.61 H, bd, J=7.7Hz, pyridinium p-H) and 8.95 ppm (2H, d, J=6.6Hz, pyridinium o-H).
In a likewise manner, starting from the compounds described in Example 43, there were obtained: (6S,5R)-6-(1R-hydroxyethyl)-2-(3-carbamoylpyridinium-methyl)penem-3-carboxylate; and (6S,5R)-6-(1R-hydroxyethyl)-2-(4-carbamoylpyridinium-methyl]-penem-3-carboxylate, Example 45 (6S,5R)-6-(1 R-hydroxyethyl)-2-[(1 -methyl-5-tetrazolylthio)-methyl]-penem-3-carboxylic acid, sodium salt A solution of p-nitrobenzyl (7S,6R)-7-( 1 R-p-nitrobenzyloxy-carbonyloxyethyl)-3-[(1 1-methyl-S- tetrazolylthio)-methyl]-2-thiacephem-4-carboxylate in chloroform was oxidized with mchloroperbenzoic acid, as described in Example 37, to give the corresponding sulphate. Without purification, this material was heated at 60 C in dry distilled tetrahydrofuran under a stream of nitrogen until expulsion of sulphur dioxide was complete.Removal of the solvent and silica gel chromatography gave p-nitrobenzyl (6S,5R)-6-(1 R-p-nitrobenzyloxycarbonyloxyethyl)-2-[( 1-methyl-S- tetrazolylthio)-methyl]-penem-3-carboxylate; #(CDCl3)1.48 (3H, d, J=7Hz, CH3-CH),3.84(1H,dd, J=2 and 5.5Hz, CH-CH-CH), 3.96 (3H, s, NCH3), 4.69 (2H, ABq, J=14Hz, CK2S), 5.20 (1 H, m, CH3-CH-CH), 5.24 (2H, s, OCH2Ar), 5.27 (2H, ABq, J=1 3Hz, OCH2Ar), 5.61(1 H, d, J=2Hz), 7.51 and 7.82 (each 2H, d, J=8Hz, Ar) and 8.02 ppm (4H, d, J=8Hz, Ar).Reaction of the above material with iron and ammonium chloride, according to the procedure described in Example 44, afforded the title product; #(D2O) 1.28 (3H, d, J=6.5Hz), 3.87 (1 H, dd, J=1 .4 and 6.3 Hz, CH-CH-CH), 4.10 (3H, s,NCH3),4.19(1H, m, OH3-CH-CH), 4.40 (2H, ABq, J=1 6Hz, CH2S) and 5.59 ppm (1 H, d, J=1.4Hz, CH-CH-S); Amax (H20) 315 nm.
Example 46 Methyl (6S,5R)-6-(1R-t-butyldimethylsilyloxyethyl)-2-nitrooxymethyl-penem-3-carboxylate A solution of methyl (7S,6R)-7-(1 R-t-butyidimethylsilyloxyethyl)-3-nitrooxymethyl-2thiacephem-4-carboxylate, prepared as described in Example 31, in chloroform was treated with 2 mol. equiv. of m-chloroperbenzoic acid at OOC to give the 1 -sulphone.Aqueous carbonic acid was added to extract the m-chlorobenzoic acid, and then the dried organic solution was gently refluxed (tlc monitoring) to give a solution of the title compound; b(CDCI3) (inter alia) 5.64 (1 H, d, J=2Hz, OH- CH-S) and 5.65 ppm (2H, ABq, J=1 5Hz, sep. of inner line 46Hz, CH20NO2) #max (CHCI3) 1790 and 1710 cm~1. In a likewise manner, starting from trichloroethyl (7S,6R)-7-(1 R-trichloroethoxycarbonyloxyethyl)-3-nitrooxymethyl-2-thiacephem-4-ca rboxylate, there was obtained: : Trichloroethyl (6S,5R)-6-( 1R-trichloroethoxycarbonyloxyethyl)-2-nitrooxymethyl-penem-3- carboxylate Example 47 Methyl (6S,5R)-6-(1 R-t-butyldimethylsilyloxyethyl)-2-hydroxymethyl-penem-3-carboxylate A solution of crude methyl (6S,5 R)-6-( 1 R-t-butyldimethylsi lyloxyethyl-2-nitrooxymethyl-penem- 3-carboxylate, prepared as described in Example 46, in 2 ml of dichloromethane was stirred for 5 minutes at OOC with 0.1 g of zinc dust and 0.1 ml of acetic acid.The reaction mixture was filtered and the solution was evaporated to give the crude title product, which was purified by silica gel chromatography (ethyl acetate:light petrol, from 1:4 to 1:1 by volume); #max (CHCI3 film) 1785, 1710 cm #(CDCl3) 0.07 (6H, s, SiMe2), 0.88 (9H, s, SiBut), 1.23 (3H, d, CH3-CH), 3.70 ( 1 H, dd, J=1 .8 and 4.5Hz, CH-CK-CH), 4.25 ( 1 H, m, CH3-CH-CH), 4.59 (2H, s, CH2OH) and 5.57 ppm ( 1 H, d, J=1 .8 Hz, CH-CH-S).
Operating in an analogous way on trichloroethyl (6S,5R)-6-(1 R-trichloroethoxycarbonyloxy ethyl)-2-nitrooxymethyl-penem-3-carboxylate, complete deblocking of the protecting groups was achieved, thus obtaining after aqueous sodium bicarbonate work up and reverse phase chromatography (water as eluant): (6S,5R)-6-(1 R-hydroxyethyl)-2-hydroxymethyl-penem-3-carboxylic acid, sodium salt; #(D2O) 1.30 (3H, d, CH3-CH), 3.88 ( 1 H, dd, J=1 and 6.3Hz, CH-CK-CH), 4.23 (1 H, m, CH3-CH-CH), 4.63 (2H, ABq, J=1 4.5Hz, separation of inner lines 4Hz, CH2OH) and 5.62 ppm (1 H, d, J=1 Hz, CH-CH-S); #max (KBr) 1765 and 1610-1590 cm-1.
Example 48 (6S,5R)-6-(1 R-hydroxyethyl)-2-carba moyloxymethyl-penem-3-carboxylic acid, sodium salt A chloroform solution of trichloroethyl (7S,6R)-7-( 1 R-trichloroethoxycarbonyloxyethyl)-3 carbamoyloxymethyl-2-thiacephem-4-carboxylate was treated with m-chloroperbenzoic acid according to the general procedure of Example 37.After work-up brief heating of the resulting 1sulphone in benzene gave trichloroethyl (6S,5R)-6-(1 R-trichloroethoxycarbonyloxyethyl)-2carbamoyloxymethyl-penem-3-carboxylate; #(CDCl3) 1.5 (3H, d, CH3-CH), 3.94 (1 H, dd, J=2 and 8Hz, CH-CH-CH), 4.73 and 4.82 (each 2H, s, OCH2CCI3), 4.8 (iH, m, CH3-CK-CH), 5.25 (2H, ABq, J=10Hz, CH20CONH2) and 5.62 ( 1 H, d, J=2Hz, CH-CH-S).
A THF solution of this material was treated with zinc dust (approx. 6 parts by weight) and 1 M aqueous sodium bihydrogen phosphate under stirring. After 3 hours stirring at 250C, another portion of zinc was added and the mixture kept under stirring for 3 hours. Work-up and reverse-phase chromatography afforded the title product; #(D2O) 1.31 (3H, d, J=6.5Hz, CH3-CH), 3.91 H, dd, J=1 .5 and 6Hz, CH-CH-CH), 4.25 (1 H, m, CH3-CH-CH), 5.19 (2H, ABq, J=1 4.5Hz, CH2OCO) and 5.66 ppm ( 1 H, d, J=1.5Hz, CH-CH-S).

Claims (78)

Claims
1. A process for the preparation of a (5R)-penem derivative of the general formula I
wherein R, represents a hydrogen atom or an organic group, R2 represents a hydrogen atom or a carboxy protecting group and Y represents a hydrogen or halogen atom or an organic group, the process comprising oxidising a 2-thiacephem derivative of the general formula II
wherein R1, R2 and Y are as above defined to give a sulphone of the general formula III
wherein Rt, R2 and Y are as above defined, and ring contracting the sulphone by extrusion of sulphur dioxide; and, if desired, converting the resultant (5R)-penem of the general formula I into another compound of the general formula I; and/or, if desired, converting the resultant compound of the general formula I into a salt thereof; and/or, if desired, obtaining a free compound of the general formula I from a salt thereof.
2. A process according to claim 1 in which the oxidation is carried out with a peracid.
3. A process according to claim 2 in which the peracid is m-chloroperbenzoic acid or peracetic acid.
4. A process according to any preceding claim in which the oxidation is carried out in an inert organic solvent at from OOC to 600 C.
5. A process according to any preceding claim in which the oxidation is carried out in an inert organic solvent at from 40C to 300 C.
6. A process according to claim 4 or claim 5 in which the inert organic solvent is chloroform or benzene.
7. A process according to any preceding claim in which the ring contraction is carried out in an inert organic solvent at ambient temperature.
8. A process according to any preceding claim in which the ring contraction is carried out in an inert organic solvent under gentle heating.
9. A process according to claim 7 or claim 8 in which the inert organic solvent for the ring contraction is chloroform or benzene.
10. A (5R)-penem derivative of the general formula I wherein R1 represents an optionally substituted aliphatic or cycloaliphatic group, and R2 and Y are as defined in claim 1 prepared by a process according to any preceding claim.
11. A {5R)-penem derivative of the general formula I wherein R, represents a straight or branched alkyl group having from 1 to
12 carbon atoms optionally substituted by one or more free or protected mercapto, amino or hydroxy groups or by a cyano group, and R2 and Y are as defined in claim 1 prepared by a process according to any of claims 1 to 9.
1 2. A (5R)-penem derivative of the general formula I wherein R1 represents a hydroxymethyl, hydroxyethyl or hydroxyisopropyl group, free or protected by a p-nitrobenzyloxycarbonyl, dimethyl-tbutyl-silyl, diphenyl-t-butyl-silyl, trimethylsilyl, 2,2,2-trichloroethoxycarbonyl, benzyl, pbromophenacyl, triphenylmethyl or pyranyl group, and R2 and Y are as defined in claim 1 prepared by a process according to any of claims 1 to 9.
13. A (5R)-penem derivative of the general formula I wherein R1 represents a monocycloalkyl group having from 4 to 7 carbon atoms, unsubstituted or substituted by one or more alkyl groups having from 1 to 6 carbon atoms and/or by one or more free or protected mercapto, amino or hydroxy groups and R2 and Y are as defined in claim 1 prepared by a process according to any of claims 1 to 9.
14. A (5R)-penem derivative of the general formula I wherein R2 represents a straight or branched alkyl group having from 1 to 6 carbon atoms, a halo-substituted alkyl group having from 1 to 6 carbon atoms, an alkenyl group having from 2 to 4 carbon atoms, an optionally substituted aryl group, an aryl substituted alkyl group the alkyl part whereof has from 1 to 6 carbon atoms and the aryl part whereof is optionally substituted, an aryloxy substituted alkyl group the alkyl part whereof has from 1 to 6 carbon atoms, or a benzhydryl, o-nitrobenzhydryl, acetonyl, tri methylsilyl, diphenyl-t-butyl-silyl-dimethyl-tbutyl-silyl, acetoxymethyl, pivaloyloxymethyl or phthalidyl group and R1 and Y are as defined in claim 1 prepared by a process according to any of claims 1 to 9.
1 5. A (5R)-penem derivative of the general formula I wherein Y represents a fluorine, chlorine or bromine atom, and R and R2 are as defined in claim 1, prepared by a process according to any of claims 1 to 9.
1 6. A (5R)-penem derivative of the general formula I wherein Y represents a) a free or protected hydroxy group; b) a formyloxy group or an acyloxy group having from 2 to 6 carbon atoms, optionally substituted by a halogen atom, by an acyl group having from 2 to 6 cabon atoms, or by an amino, hydroxy or mercapto group, the amino, hydroxy or mercapto group optionally being in a protected form; c) an unsubstituted or N-alkyl substituted carbamoyloxy group; d) an alkoxy group having from 1 to 12 carbon atoms or an alkylthio group having from 1 to 12 carbon atoms, either of which is optionally substituted by one or more halogen atoms, formyl groups, acyl groups having from 2 to 6 carbon atoms, and/or amino, hydroxy or mercapto groups optionally being in a protected form;; e) a 1-pyridinium group, unsubstituted or substituted in the meta or para position with the group -CONH2; or f) a heterocyclylthio group -5-Het wherein Het, denoting a saturated or unsaturated heterocyclic ring containing at least one oxygen, sulphur and/or nitrogen heteroatom, is preferably: A) a pentatomic or hexatomic heteromonocyclic ring, containing at least one double bond and at least one oxygen, sulphur and/or nitrogen heteroatom, such as a thiazolyl, triazolyl, thiadiazolyl, tetrazolyl, triazinyl group, unsubstituted or substituted by one or more a') alkoxy groups having from 1 to 6 carbon atoms, aliphatic acyl groups having from 2 to 6 carbon atoms, hydroxy groups and/or halogen atoms; b') alkyl groups having from 1 to 6 carbon atoms, unsubstituted or substituted by one or more hydroxy groups and/or halogen atoms; c') alkenyl groups having from 2 to 6 carbon atoms, unsubstituted or substituted by one or more hydroxy groups and/or halogen atoms; d') groups of the general formula -S-R3 wherein R3 represents a hydrogen atom or an alkyl group having from 1 to 6 carbon atoms; or groups of the general formula -S-CH2-COOR4 wherein R4 represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms or a carboxy-prctecting group; e') groups of the general formula (CH2)rnOOR4 or H=CH-COOR4 or (CH2)rnCN or (CH2)rnCONH2 or -(CH2)m-SO3H wherein m is zero, 1, 2 or 3 and R4 is as defined above; f') groups of the general formula
wherein m is as defined above, and each of R5 and R6, which may be the same or different, represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms or an aliphatic acyl group or when one of R5 and Re is hydrogen, the other may be also an amino protecting group; or B) a heterobicyclic ring, containing at least two double bonds wherein each of the condensed heteromonocyclic rings, being the same or different, is a pentatomic or hexatomic heteromonocyclic ring containing at least one oxygen, sulphur or nitrogen heteroatom, said heterobicyclic ring being unsubstituted or substituted by one or more substituents selected from a'), b'), c'), e') and f') as defined above, and R, and R2 are as defined in claim 1 prepared by a process according to any of claims 1 to 9.
17. Methyl (6S,5R)-6-(1 R-t-butyldimethylsilyloxyethyl)-2-methyl-penem-3-carboxylate prepared according to any of claims 1 to 9.
18. Methyl (6S,5R)-6-(1 R-hydroxyethyl)-2-methyl-penem-3-carboxylate prepared according to any of claims 1 to 9.
19. p-Nitrobenzyl (6S,5R)-6-(1 R-hydroxyethyl)-2-acetoxymethyl-penem-3 -carboxylate prepared according to any of claims 1 to 9.
20. p-Nitrobenzyl (6S,5R)-6-(1 R-hydroxyethyl)-2-[( 1 -methyl-5-tetrazolylthio)-methyl]-penem-3carboxylate prepared according to any of claims 1 to 9.
21. Methyl (6S,5R)-6-(1 R-t-butyldimethylsilyloxyethyl)-2-[( 1 -methyl-5-tetrazolylthio)-methyl]penem-3-carboxylate prepared according to any of claims 1 to 9.
22. (6S,5R)-6-(1 R-Hydroxyethyl)-2-(pyridinium-methyl)-penem-3-carboxylate prepared according to any of claims 1 to 9.
23. (6S,5R)-6-(1 R-Hydroxyethyl)-2-[(3-carbamoyl-pyridinium)-methyl]-penem-3-carboxylate prepared according to any of claims 1 to 9.
24. (6S,5R)-6-(1 R-Hydroxyethyl)-2-[(4-carbamoyl-pyridinium)-methyl]-penem-3-carboxylate prepared according to any of claims 1 to 9.
25. Sodium (6S,5R)-6-(1 R-hydroxyethyl)-2-[( 1 -methyl-5-tetrazolylthio)-methyl]-penem-3- carboxylate prepared according to any of claims 1 to 9.
26. Methyl (6S,5 R)-6-( 1 R-t-butyldimethylsilyloxyethyl)-2-nitrooxymethyl-penem-3-carboxylate prepared according to any of claims 1 to 9.
27. Trichloroethyl (6S,5R)-6-(1 R-trichloroethoxycarbonyloxyethyl)-2-nitrooxymethyl-penem-3- carboxylate prepared according to any of claims 1 to 9.
28. Methyl (6S,5R)-6-( 1 R-t-butyldimethylsilyloxyethyl)-2-hydroxyethyl-penem-3-carboxylate prepared according to any of claims 1 to 9.
29. Sodium (6S,5R)-6-(1 R-hydroxyethyl)-2-hydroxymethyl-penem-3-carboxylate prepared according to any of claims 1 to 9.
30. Sodium (6S,5R)-6-(1 R-hydroxyethyl)-2-carbamoyloxymethyl-penem-3-carboxylate prepared according to any of claims 1 to 9.
31. A process for the preparation of a 2-thiacephem derivative of the general formula II:
wherein R1 and R2 are as defined in claim 1 and Y represents a halogen atom, the process comprising halogenating a 2-thiacephem derivative of the general formula II wherein R, and R2 are as above defined and Y represents a hydrogen atom in an inert organic solvent, at a temperature of from 20C to 1 300C in the presence of a radical initiator and an acid scavenger.
32. A process according to claim 31 in which the halogenation is effected with Nbromosuccinimide or N-chlorosuccinimide.
33. A process according to claim 31 or claim 32 in which the radical initiator is azobisisobutyronitrile or benzoyl peroxide.
34. A process according to any of claims 31 or 33 in which the acid scavenger is an epoxide, an alkaline earth oxide or a molecular sieve.
35. A process according to any of claims 31 to 34 in which the solvent is benzene, carbon tetrachloride or ethyl formate.
36. Methyl (7S,6R)-7-( 1 R-t-butyldimethylsilyloxyethyl)-3-bromomethyl-2-thiacephem-4- carboxylate prepared according to any of claims 31 to 35.
37. Diphenyl methyl (7S,6R)-7-(1 R-t-butyldimethylsi lyloxyethyl)-3-bromo-methyl-2-thiacephem 4-carboxylate prepared according to any of claims 31 to 35.
38. Trichloroethyl (7 S,6R)-7-( 1 R-t-butyldi methylsilyloxyethyl)-3-bromomethyl-2-thiacephem-4carboxylate prepared according to any of claims 31 to 35.
39. Trichloroethyl (7S,6R)-7-( 1 R-trichloroethoxycarbonyloxyethyl)-3-bromomethyl-2thiacephem-4-carboxylate prepared according to any of claims 31 to 35.
40. t-Butyl (7S,6R)-7-(1 R-t-butyldimethylsilyloxyethyl)-3-bromomethyl-2-thiacephem-4carboxylate prepared according to any of claims 31 to 35.
41. p-Nitrobenzyl (7 S,6R)-7-( 1 R-p-nitrobenzyloxyca rbonyloxyethyl)-3-bromomethyl-2- thiacephem-4-carboxylate prepared according to any of claims 31 to 35.
42. Diphenylmethyl (7S,6R)-7-(1 R-p-nitrobenzyloxycarbonyloxyethyl)-3-bromomethyl-2thiacephem-4-carboxylate prepared according to any of claims 31 to 35.
43. Diphenylmethyl (7S,6R)-7-( 1 R-t-butyldimethylsilyloxyethyl)-3-bromomethyl-2-thiacephem- 4-carboxylate prepared according to any of claims 31 to 35.
44. A process for the preparation of a 2-thiacephem derivative of the general formula II
wherein R1 and R2 are as defined in claim 1 and Y represents a hydroxy group, the process comprising reacting a 2-thiacephem derivative of the general formula II wherein R1 and R2 are as above defined and Y represents a halogen atom with a salt of a strong inorganic acid and hydrolysing the resultant labile ester of the inorganic acid.
45. A process according to claim 44 in which the salt is silver nitrate, silver perchlorate or sodium nitrate.
46. A process according to claim 44 or claim 45 in which the reaction is carried out in an acetone: water mixture at OOC for 1 5 minutes, and the subsequent hydrolysis is carried out in the same reaction medium.
47. t-Butyl-(7S,6R)-7-( 1 R-t-butyldimethylsilyloxyethyl)-3-hydroxymethyl-2-thiacephem-4carboxylate prepared according to any of claims 44 to 46.
48. A process for the preparation of a 2-thiacephem derivative of the general formula II
wherein R1 and R2 are as defined in claim 1 and Y represents an unsubstituted or substituted N-alkyl or N-acyl carbamoyloxy group, the process comprising reacting a 2-thiacephem derivative of the general formula II wherein R1 and R2 are as above defined and Y represents a hydroxy group with an alkylisocyanate or an acylisocyanate and, if desired, deprotecting the carbamoyloxy group.
49. A process according to claim 48 in which the reaction is carried out in dichloromethane at 40C C.
50. A process according to claim 48 or claim 49 in which the deprotection is carried out by stirring with silica gel in methanol for 20 hours.
51. t-Butyl (7S,6R)-7-( 1 R-t-butyldimethylsilyloxymethyl)-3-(N-trichlornacetylcarbamoyloxy methyl-2-thiacephem-4-carboxylate prepared according to any of claims 48 to 50.
52. t-Butyl (7S,6R)-7-(1 R-t-butyldimethylsilyloxyethyl)-3-carbamoyloxymethyl-2-thiacephem-4carboxylate prepared according to any of claims 48 to 50.
53. A process for the preparation of a 2-thiacephem derivative of the general formula II
wherein R1 and R2 are as defined in claim 1 and Y represents an acyloxy group, the process comprising reacting a 2-thiacephem derivative of the general formula II wherein R1 and R2 are as above defined and Y represents a halogen atom with a carboxylic acid salt.
54. A process according to claim 53 in which the reaction is carried out in dichloromethane at 50C with addition of the salt portionwise over 3 days.
55. Methyl (7 S,6R)-7-( 1 R-t-butyidimethylsilyloxyethyl)-3-formyloxymethyl-2-thiacephe m-4carboxylate prepared according to claim 53 or claim 54.
56. t-Butyl (7 S,6R)-7-( 1 R-t-butyldi methylsilyloxyethyl)-3-formyloxymethyl-2-thiacephem-4carboxylate prepared according to claim 53 or claim 54.
57. Diphenylmethyl (7S,6R)-(1 R-t-butyldimethylsilyloxyethyl)-3-formyloxymethyl-2-thiacephem4-carboxylate prepared according to claim 53 or claim 54.
58. Methyl (7S,6R)-7-(1R-t-butyidimethylsilyloxyethyl)-3-acetoxymethyl-2-thiacephem-4- carboxylate prepared according to claim 53 or claim 54.
59. t-Butyl (7S,6R)-7-(1 R-t-butyidimethylsilyloxyethyl)-3-acetoxymethyl-2-thiacephem-4- carboxylate prepared according to claim 53 or claim 54.
60. Diphenylmethyl (7S,6R)-7-(1 R-t-butyidimethyl siloxyethyl)-3-acetoxymethyl-2-thiacephem4-carboxylate prepared according to claim 53 or claim 54.
61. Trichloroethyl (7S,6R)-6-( 1 R-trichloroethoxycarbonyloxyethyl)-3-acetoxymethyl-2- thiacephem-4-carboxylate prepared according to claim 53 or claim 54.
62. A process for the preparation of a 2-thiacephem derivative of the general formula II
wherein R1 and R2 are as defined in claims 1 to 6 and Y represents a -S-Het group as defined in claim 1 6, the process comprising reacting a 2-thiacephem derivative of the general formula II wherein R1 and R2 are as above defined and Y represents a halogen atom in an organic solvent with a compound of the formula HS-Het in the presence of a base or with a preformed sodium salt of the compound HS-Het.
63. A process according to claim 62 in which the solvent is tetrahydrofuran, acetone, acetonitrile or dimethylformamide.
64. A process according to claim 62 or claim 63 in which the reaction is carried out overnight at room temperature.
65. A process according to any of claims 62 to 64 in which the base is triethylamine.
66. Methyl (7S,6R)-7-(1 R-t-butyldimethylsi!yloxyethyl)-3-[( 1 -methyl-5-tetrazolylthio)-methyl]-2- thiacephem-4-carboxylate prepared according to any of claims 62 to 65.
67. t-Butyl (7S,6R)- 1 R-t-butyldimethylsilyloxyethyl)-3-[( 1 -methyl-5-tetrazolylthio)-methyl]-2thiacephem-4-carboxylate prepared according to any of claims 62 to 65.
68. Diphenylmethyl (7S,6R)-7-(1 R-t-butyldimethylsilyloxyethyl)-3-[(8-aminotetrazol-[ 1 S-b]- pyridazin-6-ylthio)-methyl]-2-thiacephem-4-carboxylate prepared according to any of claims 62 to 65.
69. A process for the preparation of a 2-thiacephem derivative of the general formula II
wherein R1 and R2 are as defined in claim 1 and Y is a 1 -pyridinium group, unsubstituted or substituted in the meta or para position with a carbamoyl group, the process comprising reacting a 2-thiacephem derivative of the general formula II wherein R1 and R2 are as above defined and Y represents a halogen atom with pyridine, nicotinamide or isonicotinamide.
70. (7S,6R)-7-( 1 R-t-butyldimethylsilyloxyethyl)-4-diphenylmethoxycarbonyl-3-(pyridinium- methyl)-2-thiacephem bromide prepared according to claim 69.
71. (7S,6 R)-7-( 1 R)-p-nitrobenzyloxywarbonyloxyethyl)-4-p-nitrobenzyloxyCa rbonyl-3 (pyridinium-methyl)-2-thiacephem bromide prepared according to claim 69.
72. (7S,6R)-7-( 1 R-p-nitrobenzyloxycarbonyloxyethyl)-4-p-n itrobenzyloxycarbonyl-3-(3carbamoylpyridinium-methyl)-2-thiacephem bromide prepared according to claim 69.
73. (7 S,6R)-7-( 1 R)-p-nitrobenzyloxyca rbonyloxyethyl)-4-p-nitrobenzyloxywarbonyl-3-(4- carbamoylpyridinium-methyl)-2-thiacephem-bromide prepared according to claim 69.
74. A process for the preparation of a 2-thiacephem derivative of the general formula II
wherein R1 and R2 are as defined in claim 1 and Y is as defined in claim 8, the process comprising halogenating a compound of the general formula IV
wherein R1 and R2 are as above defined and Z represents i) a group of the formula SR7 wherein R7 represents an alkyl group having from 1 to 8 carbon atoms, a phenyl or tolyl group, or preferably, a heterocyclic group, especially a 2-benzothiazolylthio or 1-methyl-5-tetrazolylthio group, ii) a group of the formula SCOR8 wherein R8 represents an optionally substituted lower alkyl group, preferably a methyl group, iii) a group of the formula
wherein R9 and R10 independently represent lower alkyl or aryl groups, or together with the dicarboxyamino group form a heterocyclic ring, preferably a succinimido or phthalimido group, or iv) a group of the formula
wherein R7 represents an optionally substituted lower alkyl or aryl group, preferably a methyl, phenyl or p-tolyl group; ozonolysing the resultant compound of the general formula V
wherein R1, R2 and Z are as above defined and Y represents a halogen atom; and transforming the resultant compound of the general formula VII
wherein R,, R2, Y and Z are as above defined into a compound of the general formula IX
wherein R1, R2, Y and Z are as above defined, and L represents a halogen atom, an alkane sulphonyloxy group or an arenesulphonyloxy group; and cyclizing the compound of the general formula IX.
75. A process for the preparation of a 2-thiacephem derivative of the general formula II
wherein R1 and R2 are as defined in claim 1 and Y represents a hydrogen atom, the process comprising ozonolysing a compound of the general formula IV
wherein R1 and R2 are as defined in claim 1 and Z is as defined in claim 74, converting the resultant compound of the general formula VI
into a compound of the general formula VIII
wherein R1, R2, Land Z are as defined in claim 74, and cyclizing the compound of the general formula VIII by treatment with a salt of hydrogen sulphide with an organic or inorganic base.
76. A 2-thiacephem-1 ,1 -dioxide of the general formula Ill:
wherein R1, R2 and Y are as defined in claim 1.
77. (7S,6R)-7-( 1 R-t-butyldimethylsilyloxyethyl)-3-methyl-4-methoxycarbonyl-2-thiacephem- 1,1-dioxide.
78. (7S,6R)-7-(1R-hydroxyethyl)-3-methyl-4-methoxycarbonyl-2-thiacephem-1,1-dioxide.
GB08332756A 1982-12-08 1983-12-08 Preparation of (5r)-penem derivatives Expired GB2131432B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB08332756A GB2131432B (en) 1982-12-08 1983-12-08 Preparation of (5r)-penem derivatives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8235058 1982-12-08
GB838323129A GB8323129D0 (en) 1983-08-27 1983-08-27 2-thiacephems and penems
GB08332756A GB2131432B (en) 1982-12-08 1983-12-08 Preparation of (5r)-penem derivatives

Publications (3)

Publication Number Publication Date
GB8332756D0 GB8332756D0 (en) 1984-01-18
GB2131432A true GB2131432A (en) 1984-06-20
GB2131432B GB2131432B (en) 1986-10-15

Family

ID=27261866

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08332756A Expired GB2131432B (en) 1982-12-08 1983-12-08 Preparation of (5r)-penem derivatives

Country Status (1)

Country Link
GB (1) GB2131432B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0255307A1 (en) * 1986-07-29 1988-02-03 Pfizer Inc. Process for the synthesis of penems
EP0167100B1 (en) * 1984-06-29 1990-12-05 FARMITALIA CARLO ERBA S.r.l. Penem derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0167100B1 (en) * 1984-06-29 1990-12-05 FARMITALIA CARLO ERBA S.r.l. Penem derivatives
EP0255307A1 (en) * 1986-07-29 1988-02-03 Pfizer Inc. Process for the synthesis of penems

Also Published As

Publication number Publication date
GB2131432B (en) 1986-10-15
GB8332756D0 (en) 1984-01-18

Similar Documents

Publication Publication Date Title
JPH0314037B2 (en)
US4585767A (en) Antibacterial penem derivatives
US4713450A (en) 2-thiacephems and (5R) penems derivatives
EP0130025B1 (en) 2-alkylthiopenem derivatives
AU634876B2 (en) Novel 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them
EP0099059B1 (en) Antibacterial penem derivatives
KR870000525B1 (en) Process for preparing 2-azacycloalkyl thio penem derivatives
GB2131432A (en) Preparation of (5R)-penem derivatives
EP0091576B1 (en) 7-oxo-4-thia-1-azabicyclo(3,2,0)heptane derivatives
JPS588085A (en) Manufacture of optically active trans-6- substituted-5(r)-2-penem-3-carboxylic acid derivatives, manufacture and compounds obtained thereby
GB2166441A (en) Preparation of 2-thiacephems
JPH0225914B2 (en)
PL163376B1 (en) Method of obtaining pheneme derivatives
EP0223397B1 (en) Process for 2-(1-oxo-3-thiolanyl)-2-penem antibiotics
KR870000326B1 (en) Process for preparing 2-alkylthio-penem derivatives
GB2195627A (en) Penem derivatives
GB2124614A (en) Easily cleavable carboxylic esters and their use in the synthesis of penems and other b-lactam antibiotics
KR870000524B1 (en) Process for preparing 2-dioxacycloalkyl thiopenem derivatives
IE871080L (en) Preparing 2-thiacephems
PL150254B1 (en)
JPH04368365A (en) Production of azetidinone derivative
GB2142019A (en) Novel azetidinone intermediates and their use in the synthesis of 2-(substituted methyl) penem-3-carboxylates
JPS6011463A (en) Novel azetidinone compound
JPS63188684A (en) Production of 7-oxo-4-thia-1-azabicyclo(3. 2. 0)hept-2-ene derivative
JPS6056986A (en) Manufacture of 7-acylamino-3-hydroxycephem-4- carboxylic acids and 7-acylamino-3-hydroxy-1- dethia-1-oxacephem-4-carboxylic acids

Legal Events

Date Code Title Description
732 Registration of transactions, instruments or events in the register (sect. 32/1977)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19941208